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1 Short summary 
The WNT signaling pathway regulates many different cellular processes, among them 
lymphopoiesis. Especially its influence on B cell maturation is not well understood, but it 
is clear that abnormal pathway activity is one of the hallmarks of B cell neoplasia like 
chronic lymphocytic leukemia (CLL). As one of the downstream effectors of the WNT 
signaling cascade, LEF1 (Lymphoid enhancer-binding factor 1) was suggested to play a 
pivotal role in B maturation as well as in the development and in sustaining of neoplasia 
like CLL. The goal of this project was to develop an easily adaptable LEF1 dependent 
mouse model to elucidate the effects of LEF1 overexpression in B cells and other tissues. 
Furthermore, it was designed to test whether the LEF1 overexpression, which is common 
in several cancers, has oncogenic potential. The secondary goal of this project is to test 
if newly developed NO-ASA derivates, a known class of WNT inhibitors, might provide a 
feasible strategy for experimental treatment of chronic lymphocytic leukemia. The 
substances were tested for their efficacy, selectivity and bioavailability.  
The newly developed R26lef1 mouse model is highly adaptable, by using the Cre-loxP-
system, and allows specific transgene expression in different tissues, cell types or 
developmental stages. The expression is stable and allows long-term experiments. The 
induction of expression by CD19 controlled Cre expression resulted in transgene 
expression in 76% of all B cells. The overexpression of LEF1 in the murine B cells leads 
to increased WNT signaling, which results in 3-6% less B cells in the lymphocytes of the 
peripheral blood, bone marrow and spleen when compared to control mice. Neither 
phenotypical differences of the lymphocytes nor a leukemia induction were detected in an 
average monitoring period of over 12 month. The overall survival was also not significantly 
altered, but LEF1 expressing mice developed more often cancers, which possibly reflects 
a reduced immune surveillance. The induction of LEF1 expression by a Cr2-cre construct 
revealed no significant differences to control mice. A CMV dependent Cre expression led 
to an abnormal skull formation resulting in a shortened snout. This phenotype is highly 
similar to Axin2 knock-out mice, which represent a strain with abnormally active WNT 
signaling. In a nutshell, the experiments show that the R26lef1 mouse model is functional 
and allows stable transgene expression in different tissues in long term experiments. The 
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LEF1 overexpression in B cells seems not to hamper maturation, but rather affects 
proliferation. Overall LEF1 overexpression failed to induce neoplasia.  
In several studies, including this one, NO-ASAs, which were reported to inhibit WNT 
signaling, proved to be an effective and selective substances to drive chronic lymphocytic 
leukemia cells into apoptosis. mRNA analysis of CLL cells treated with the para isomere 
of NO-ASA, revealed an increased expression of heat-shock proteins and other stress 
related genes, which hint to an regulation by the NFκB signaling pathway. No association 
with WNT signaling pathway was found in this study. In order to further increase efficacy 
and selectivity, several derivatives of para-NO-ASA were developed. Experiments with 
the new NO-ASA derivatives, conducted in parallel to this study, showed an increase in 
selectivity and efficacy especially for two candidate substances (B9 & B12). These 
substances were used in in vivo experiments. B9 significantly inhibited the growth of JVM3 
tumors, with a maximum inhibition ratio of 65% in a xenograft mouse model and was well 
tolerated (8 mg/kg, every 2nd day, intraperitoneal). B12 failed to inhibit tumor growth 
compared to the control group. Overall, B9 is superior to its parent compound and shows 
promise for a future use as a drug in the treatment of chronic lymphocytic leukemia. 
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2 Introduction 
2.1 The WNT signaling pathway 
In the year 1982 Roel Nusse and Harold Varnus discovered the first WNT gene, at that 
time called int1, which proved to be the starting point for the discovery of a whole signaling 
network as we know it today (Nusse and Varmus, 1982). First striking evidence for 
functional activity of this gene came from mice which overexpressed int1 in their mammary 
glands and developed corresponding tumors (Tsukamoto et al., 1988). These 
experiments proved the oncogenic potential of the gene. More insight into the function of 
this pathway came from experiments with Drosophila melanogaster, which soon became 
one of the most important models for WNT research. In this model organism int1 was 
identified as a segment polarity gene during embryo development (Rijsewijk et al., 1987). 
A mutant of this gene resulted in flies without wings and was hence named wingless. In 
1990 Thomas and Capecchi generated the first int1 deficient mice (Thomas and 
Capecchi, 1990). Their work showed that these null mice died prenatal with severe 
disturbances in the development of the midbrain and cerebellum. Around the 1990s the 
known int genes were renamed to WNT (Wingless-related integration site), with int1 now 
designated as wnt1. In human 19 WNT genes are known, which can be subdivided into 
12 families of highly similar members. The gap between the WNTs, which are extracellular 
signaling molecules, to intracellular signaling cascade was closed in the early 90s. In 1993 
it was shown that a truncated form of APC (adenomatous polyposis coli) induces tumors 
in the gut and interacts with a protein called β-catenin (Rubinfeld et al., 1993; Su et al., 
1993). The β-catenin proved to be a homologue of a Drosophila gene named armadillo. 
This gene also belongs to the group of segment polarity genes, which led the way back 
to wnt1. The circle was closed by identifying GSK3 (Glycogen Synthase Kinase 3) as an 
interaction partner of Armadillo, which was negatively regulated by WNT/Wingless 
(Siegfried et al., 1992). These findings subsequently led to the theory of a destruction 
complex that regulates β-catenin levels via phosphorylation in a WNT dependent manner. 
Together with the observation that β-catenin can enter the nucleus and its levels are 
commonly increased by WNT stimulation, it became clear that the protein is the central 
messenger of the signaling pathway (Funayama et al., 1995; Riggleman et al., 1990). In 
1996 another important step was made, as β-catenin was shown to interact with 
transcription factors from the TCF/LEF1 family (Behrens et al., 1996; Huber et al., 1996; 
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Molenaar et al., 1996). This finalized the signal transduction from the extracellular WNT 
to the regulation of gene expression. Today our picture from the WNT signaling pathway 
is much more complex and numerous modulators and functions have been identified. 
The great complexity of the pathway alone speaks of an early development in the history 
of life. The current view determines appearance of WNT genes to about 650 Million years 
ago. Wnt genes have been identified in cnidarians, chordates, echinoderms, mollusks, 
annelids, nematodes and arthropods. No wnt genes were found in unicellular eukaryotes, 
cellular slime molds or choanoflagellates (Guder et al., 2006).  
Despite the early origin the wnt genes, several other important pathway members, like the 
tcf/lef1 transcription factors, are usually highly conserved. One example is LEF1, like 
shown in Figure 1 for the phylum of the chordate. 
 
Figure 1 Amino acid sequence conservation of LEF1 in mouse (Mus musculus), human (Homo sapiens), zebra 
fish (Danio rerio) and African clawed frog (Xenopus laevis). 
 
The amino acid sequences of LEF1 of the four species from the chordate phylum are 
highly similar (see Figure 1). All four species share about 70% identical amino acids. 
Between the two mammals the sequence identity is even 97.2%. The remaining 2.8% are 
not identical, but highly similar amino acids (AA).  
The broad scope of the WNT gene family in chordate and the high conservation show the 
importance of this pathway and hint its complexity in function and structure. During the 
first 20 years, after the discovery of int1, a signaling pathway with β-catenin as central 
messenger protein emerged. Over the last decade a more sophisticated model has arisen, 
which subdivides the WNT signaling pathway in three different branches. These are the 
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WNT/PCP and the WNT/Ca2+ (Calcium) signaling pathways, which are also referred to as 
non-canonical pathways, and the canonical or WNT/β-catenin pathway. Each branch of 
this WNT signaling network has different functions and key players, which often integrate 
information in direct interaction, but usually share up-stream components like receptors 
and extracellular regulators.  
 
2.2 WNTs, Receptors, Regulators and Pathways 
The three different branches of the WNT signaling network use several different 
components for their function. However all three are regulated by WNT proteins and their 
corresponding receptors. The following Figure 2 shows an overview of the WNT signaling 
network and its modulation on receptor level. 
 
Figure 2 The WNT signaling network on receptor level. In left upper corner a WNT producing cell is depicted. 
The WNTs are either secreted directly or packed into vesicular structures. In the extracellular space WNT 
proteins, which can be bound and neutralized by WIFs (WNT inhibitory factor) and sFRPs (Secreted frizzled-
related protein), are shown. On the plasma membrane of the receiving cell several WNT binding FZD receptors 
are depicted, which activate, in correspondence with co-receptors like RYK, ROR or LRP5/6 (Low-density 
lipoprotein receptor-related protein) different branches of the WNT signaling network. DKK and SOST/WISE 
inhibit WNT/β-catenin signaling while ZNRF3 facilitates FZD receptor degradation, which can be inhibited by 
Rspondin. Designed with motifolio objects.  
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2.2.1 WNT proteins 
The proteins after which the whole network is designated, are small secreted signaling 
proteins of about 40 kDa (Kilo Dalton) (Cheyette and Moon, 2003; Guder et al., 2006). 
WNTs in general carry a signal peptide sequence that marks them for secretion, as well 
as glycosylation and lipidation sites. These sites are of high importance for the activity and 
therefore highly conserved (Cheyette and Moon, 2003). For example human WNT1 
carries as much as four N-glycosilation sites and two sites for lipid modification (Cysteine 
93 and Serine 224). The glycosylation appears not to be mandatory for, but promotes 
activity and secretion (Tang et al., 2012). Additionally, the lipidation of WNT proteins 
influences the activity, the secretion and their ability to interact with the extracellular matrix 
(ECM) (Doubravska et al., 2011). While acetylation and subsequent palmitoylated of the 
serine influences WNT3a activity, the lipidation on the cysteine residue proved to be 
important for its intracellular transport (Takada et al., 2006). 
 
Intracellular transport and secretion 
WNT proteins are translated at the rough endoplasmatic reticulum (ER) and transported 
via the Golgi apparatus to the plasma membrane (PM). A central element of intracellular 
WNT transport appears to be the lipidation. This post-translational modification is primed 
by Porcn, an acetyl transferase localized in the ER. The importance of this step is 
underlined by in vivo experiments performed by Biechele et al., where porcn mutants led 
to developmental defects in mice. These effects appeared to be similar to a defective WNT 
signaling (Biechele et al., 2011). 
How WNT proteins travel through the tissue after their release is not well understood. 
Multiple vectors like lipoprotein particles and exosomes have been described (Gross et 
al., 2012; Neumann et al., 2009; Panáková et al., 2005). Also interactions with the ECM 
influence WNT transport and activity (Lin and Perrimon, 2000). Despite earlier 
assumptions WNT signaling can also occur over long distances, as shown 2008 by 
Katanaev et al. (Katanaev et al., 2008). 
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2.2.2 WNT receptors 
As we know today WNT proteins are recognized by a variety of different receptors. The 
largest group is the Frizzled (FZD) receptor family. All members of this family share a 
large conserved cysteine-rich domain (CRD), which binds WNT proteins with a high 
affinity (Janda et al., 2012). The Frizzled receptors are central proteins for all three 
branches of the WNT signaling network. Together with the co-receptor LRP5/6 (Low-
density lipoprotein receptor-related protein 5/6) Frizzled receptors regulate the β-catenin 
dependent signaling, whereas they influence WNT/Ca2+ and WNT/PCP signaling by 
associating with tyrosine kinases like ROR or RYK (Macheda et al., 2012; Sato et al., 
2010; Yoshikawa et al., 2003). It has to be noted that WNT signaling via ROR and RYK 
seems not to require Frizzled receptors. The interaction of all these receptors and co-
receptors determines the outcome of the WNT signaling event and they’re therefore tightly 
controlled. One example is ZNFR3 expression, which controls the amount of available 
Frizzled receptors by its E3 ubiquitin ligase activity (see Figure 2) (Hao et al., 2012). 
 
2.2.3 Disheveled  
Downstream of the Frizzled receptors act the Disheveled proteins, which play an 
important role in signal transduction from Frizzled receptors. These proteins regulate the 
canonical as well as non-canonical signaling cascades and have great influence on signal 
integration. The Disheveled proteins share three highly conserved domains in their 
structure, an amino terminal PIX domain, a central PDZ and a carboxy terminal DEP 
domain (Wharton, 2003). At the level of Disheveled Frizzled dependent WNT signaling 
splits into its branches, the non-canonical (WNT/Ca2+ and WNT/PCP) and the canonical 
WNT-signaling (WNT/β-catenin). Signaling through WNT/β-catenin signaling cascade 
dependents on the PIX and PDZ domains of Disheveled, while non-canonical WNT 
signaling utilizes the PDZ and the DEP domains (Habas and Dawid, 2005). As a general 
mechanism Disheveled is recruited to the Frizzled receptor upon WNT binding, where it 
interacts with the downstream effectors like Axin, Rho or Rac. The outcome of frizzled 
dependent WNT signaling appears to be rather triggered than by receptor context than 
regulation of Disheveled, as it is crucial for all WNT signaling branches (Habas and Dawid, 
2005).  
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2.2.4 Extracellular WNT modulation 
The WNT signaling network is tightly controlled on all levels to ensure homeostasis of this 
important signaling pathway. In the extracellular space a great variety of WNT modulators 
is present to achieve this goal. Few agonistic extracellular WNT modulators are known, 
one example is R-spondin. R-spondin decreases the ubiquitin ligase activity of ZNRF3, 
which leads to a stabilization of Frizzled and subsequent to increased β-catenin 
dependent WNT signaling (see Figure 2) (Hao et al., 2012).  
Of the antagonistic extracellular WNT modulators the most prominent protein families are 
the WIF, the sFRP, the DKK and the cysteine knot family proteins SOST and WISE (see 
Figure 2). The WIF and sFRP family members can bind WNT proteins directly and thereby 
neutralize their activity (Hsieh et al., 1999; Jaspard et al., 2000). The binding affinity of the 
individual inhibitory protein to different WNT protein differs, which allows fine tuning of 
WNT activity in different tissues. DKK proteins interact with the LRP6 co-receptor and 
together with the DKK receptors of the Kremen family lead to its internalization (Mao et 
al., 2002; Mishra et al., 2012).  
 
2.3 Non-canonical WNT signaling 
Non-canonical WNT signaling summarizes signal transduction independent of β-catenin. 
The first evidence for the existence of an alternative outcome for WNT signaling came 
from experiments with Xenopus leavis. Injection of WNT5a into Xenopus embryos lead to 
developmental defects in head and tail, which resulted from perturbed cellular movements 
(Moon et al., 1993). Later experiments identified WNT5a as a major regulator of the two 
distinct branches of non-canonical WNT signaling, the WNT/Ca2+ and the WNT/PCP 
pathway (see Figure 3). 
The WNT/PCP pathway is named after its crucial role in forming planar cellular polarity 
(PCP) during embryogenesis. Cell polarity is important for many cell types, for epithelial 
cells with their apical-basal orientation or for directed movement of cells along a gradient 
of a morphogen. Probably due to the regulation of the cell polarity, the signaling cascade 
regulates many biological processes linked to this topic, like mitotic spindle orientation, 
convergent extension, neural tube closure or hair orientation (Bellaïche et al., 2001; Guo 
et al., 2004; Myers et al., 2002).  
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Figure 3 The non-canonical WNT signaling. WNT proteins bind to the FZD receptor which activates via DVL 
either the WNT/PCP pathway via RAC/MAPK or RHO/ROCK signaling. The small GTPases can also be bypassed 
by ROR dependent signaling, which independently activates JNK. The second alternative, the WNT/Ca2+ 
pathway, the activation signal is transduced from DVL via heterotrimeric G-proteins to PLC, which transforms 
PIP2 to IP3 and increases the intracellular calcium by release from the ER controlled by the IP3R. Intracellular 
Ca2+ in term activates PKC or CamKII. The third alternative is Src kinase activation facilitated by RYK signaling. 
 
The activation of the WNT/PCP pathway (see Figure 3) is usually associated to WNT5A, 
WNT5B and WNT11, this however cannot be generalized and is also depend on receptor 
regulation (Dabdoub et al., 2003; Heisenberg et al., 2000; Kilian et al., 2003). The WNT 
proteins can bind either to the Frizzled receptor or to alternative WNT receptors like ROR2 
(see Figure 3). If WNT bind to the Frizzled receptor Disheveled is recruited and relays the 
signal via small GTPases (Boutros et al., 1998; Yamanaka et al., 2002). These small 
GTPases regulate JNK dependent gene expression via ROCK or the MAPK cascade.  
The WNT/Ca2+ signaling is the second major outcome of non-canonical WNT signaling 
that we know today (see Figure 3). In this branch of WNT cascade the signal is transduced 
from the Frizzled receptor via heterotrimeric G proteins. These G proteins regulate several 
targets, among them Phospholipase C (PLC), which leads to an increased transformation 
of phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol-1,4,5-triphosphate (IP3). IP3 in 
term induces the release of calcium from the endoplasmatic reticulum (ER). This increase 
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of cytosolic Ca2+ can activate CaMKII (Kühl et al., 2000). This Ca2+ dependent kinase 
regulates the Nemo-like kinase (NLK), which can induce β-catenin phosphorylation and 
subsequently inhibits WNT/β-catenin signaling (Ishitani et al., 2003; Saneyoshi et al., 
2002).  
 
2.4 β-catenin dependent WNT signaling 
The WNT/β-catenin is the historically first described branch of the WNT signaling network 
and it is named after its central messenger protein β-catenin. When the pathway is inactive 
a so called destruction complex consisting of Axin, APC and GSK3β assembles and 
phosphorylates β-catenin. The phosphorylation marks β-catenin for ubiquitin ligation by 
β-TrCP, which leads to its degradation in proteasomes (see Figure 4). In this off-state no 
β-catenin is found in the nucleus and WNT dependent gene expression is repressed. 
When WNT proteins bind to their corresponding Frizzled, the LRP5/6 co-receptors are 
recruited and the cascade is switched on. The ligand binding iduces the phosphorylation 
of the intracellular domain of LRP. This phosphorylation is performed by GSK3β or CK1 
activity. The phosphorylated LRP recruits Axin in a Disheveled dependent manner, which 
thereby is no longer available for the formation of the destruction complex. This allows β-
catenin to escape phosphorylation and subsequent degradation. The protein accumulates 
in the cytoplasm. The β-catenin stabilization initiates its transport into the nucleus, where 
it interacts with the transcription factors of the LEF1/TCF family. β-catenin forms a 
complex with the transcription factors and CBP (CREP-binding protein) which induces 
WNT/β-catenin dependent gene expression (see Figure 4).    
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Figure 4 WNT/β-catenin pathway. In the OFF state (left), the WNT proteins are not bound to the receptor. The 
destruction complex consisting of Axin, GSK3, CK1, APC and β-catenin can form in the absence of active WNT 
signaling. β-catenin is phosphorylated, ubiquitinated and subsequently degraded in the proteasome. In the 
nucleus TCF/LEF1 transcription factors bind DNA Deoxyribonucleic acid) and recruit TLE and HDAC to repress 
gene expression. In the ON state (right) WNT proteins bind to the FZD receptor and LRP5/6 is recruited and 
phosphorylated by GSK3 and CK1. Axin is recruited to the receptor complex and is no longer available to 
stabilize the destruction complex. The central messenger β-catenin is no longer degraded and accumulates in 
the cytoplasm. It translocates to the cytoplasm, where it transactivates TCF/LEF1 transcription factors. The 
complex recruits CBP and enhances expression of WNT target genes. Designed with motifolio objects. 
 
Like other pathways, the WNT/β-catenin pathway is tightly regulated on all levels. The 
following chapters will give insight into some of these mechanisms on the level of the 
receptor complex, the destruction complex and in the nucleus.  
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The receptor complex 
The receptor complex for WNT/β-catenin signaling consists of a Frizzled receptor, 
Disheveled and a LRP5/6 co-receptor. The co-receptor LRP5/6 is an essential part, as it 
is required to recruit Axin to the complex (Tamai et al., 2000). The docking site of Axin on 
LRP5/6 is located on the cytoplasmatic tail, which consist of five PPPS/TP motifs. 
Phosphorylation of this motifs allows Axin binding to LRP5/6 (Tamai et al., 2004). In the 
phosphorylation of the PPPS/TP motifs GSK3β appears to play an important role, as it 
can mediate serine/threonine phosphorylation in all five motifs (Zeng et al., 2005). Other 
kinases, like CK1γ, can induce LRP5/6 phosphorylation, too (Davidson et al., 2005). 
Despite the growing knowledge of the function and regulation of LRP phosphorylation the 
whole process is not well understood.  
 
The β-catenin destruction complex 
For the activity of the destruction complex the regulation of Axin localization and stability 
is of outmost importance. In the destruction complex Axin acts as scaffold protein and is 
indispensable for its function. Compared to other components the expression of Axin is 
extremely low and it was identified as cellular rate limiting component for canonical WNT 
signaling (Lee et al., 2003). A well-established regulation mechanism is the stabilization 
of Axin by GSK3β mediated phosphorylation, which overall inhibits WNT signaling 
(Yamamoto et al., 1999). Vice versa, Willert and colleagues demonstrated that WNT 
induced dephosphorylation of Axin released β-catenin from the destruction complex 
(Willert et al., 1999). Another Axin dependent regulation mechanism was discovered by 
screening for WNT inhibitors. Substances like JW55 and XAV939 stabilize Axin1 or Axin2 
and therefore act as a negative regulator for canonical WNT signaling. XAV939 and JW55 
inhibit the tankyrase enzymes, which enhances the PARsylation of the scaffold protein 
and thereby inhibit its proteosomal degradation (Franch-Marro et al., 2008; Waaler et al., 
2012). This is often associated with the expression of Axin2, which is part of a 
physiological negative feedback loop and can replace Axin1 in its function (see Figure 5). 
The activation of the WNT signaling pathway induces Axin2 expression, which in term can 
serve as scaffold protein in the destruction complex, replacing Axin1. Due to its WNT 
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dependent expression pattern Axin2 commonly is used to detect WNT activity in vitro and 
in vivo (Jho et al., 2002; Lustig et al., 2002). 
 
 
Figure 5 Axin2 negative feedback loop. The central messenger protein β-catenin transactivates the 
transcription factors TCF/LEF1 and the CBP is recruited to the complex. Target gene expression is enhanced, 
which includes Axin2. Axin2 is translated in the cytoplasm and stabilizes the destruction complex of Axin2, 
GSK3, CK1 and APC. Formation of the destruction complex leads to a rapid decrease in cytosolic β-catenin. 
Designed with motifolio objects.   
GSK3 is the second important member of the multiprotein destruction complex, as it is 
responsible for β-catenin phosphorylation (Peifer et al., 1994). As mentioned before, Axin 
can be protected from degradation by GSK3 dependent phosphorylation, thus stabilizing 
the whole destruction complex (Yamamoto et al., 1999). Together with APC the kinases 
CK1 and GSK3 are bound to Axin and form the destruction complex. β-catenin binds 
predominantly to APC and Axin and is primed by phosphorylation of Ser-45 by CK1α. 
Subsequently GSK3 adds phosphorylation of Thr-41, Ser-37 and Ser-33, which marks the 
messenger protein for the ligation with Ubiquitin by β-TrCP and thereby for degradation 
(Kimelman and Xu, 2006; Wu and Pan, 2010). In order to induce β-catenin dependent 
WNT signaling the inhibition of GSK3 is an often used strategy. Several inhibitors like LiCl 
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(Lithium chloride) or SB216763 were shown to activate canonical WNT signaling by 
inhibition of β-catenin phosphorylation through GSK3 (Klein and Melton, 1996; Meijer et 
al., 2004). A great disadvantage of GSK3 inhibition to induce WNT signaling is the 
widespread function of GSK3 kinases, as they also are central parts of NFAT, mTOR or 
insulin signaling (Beals et al., 1997; Ding et al., 2000; Inoki et al., 2006).  
Additional to the above mentioned major players, several other proteins are important for 
the function of the destruction complex. For example, Sox9 can affect the subcellular 
localization of several members of the destruction complex. Sox9 is able to induce 
relocalization of β-TrCP, Axin, CK1α and GSK3 to the nucleus which leads to an enhanced 
phosphorylation of β-catenin and thereby inhibits its transcriptional activity (Topol et al., 
2009). Together with proteasomes present in the nucleus, the nuclear destruction 
complex is able to degrade β-catenin, too (Reits et al., 1997; Topol et al., 2009).  
 
The central messenger protein β-catenin 
Before β-catenin was identified to be the central messenger protein for the canonical WNT 
signaling, it was known as an integral part of adherens junctions. The general structure of 
the protein consists of three domains, an N terminal domain, a large central armadillo 
repeat domain and a C terminal transactivation domain. While the N terminal domain 
carries the phosphorylation sites for GSK3 and other kinases, the armadillo repeat domain 
acts as a binding site for multiple interaction partners like α-catenin. The C terminal 
domain is important for the transcriptional activity of β-catenin, as it transactivates for 
example the transcription factors from the TCF/LEF1 family (Daniels et al., 2001). Up 
today 27 binary interactions of β-catenin have been described, which reflects its central 
role and high regulation.  
In most cell types β-catenin is present in two distinct pools, the cytosolic and in the 
cytoskeleton, for example in cell-cell junctions bound to cadherins. The cytosolic pool is 
subjected to a constant turnover, as newly translated β-catenin is rapidly degraded by the 
destruction machinery in absence of WNT signaling. Upon WNT ligand binding the 
cytosolic amount of the messenger proteins increases. To subsequently exercise its 
transcriptional activity, the messenger protein has to shuttle from the cytosol into the 
nucleus.  
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β-catenin itself carries no nuclear localization signal and the mechanisms underlying its 
transport into the nucleus are still somewhat elusive. Early experiments showed that the 
overexpression of LEF1 somehow led to an nuclear localization (Huber et al., 1996). It 
was suggested that the transcriptionfactor, which carries a NLS, plays a role in the nuclear 
import mechanism of β-catenin, possibly by transporting the messenger protein piggyback 
into the nucleus (Kim and Hay, 2001). Also APC and Axin have been suggested to 
participate in the import/export of β-catenin from the nucleus. Both proteins can directly 
interact with the messenger protein and carry a NLS as well as a nuclear export signal 
(NES). They were shown to regulate the import and the export of nuclear β-catenin (Cong 
and Varmus, 2004; Henderson, 2000).  
 
The TCF/LEF1 family of transcription factors 
In the nucleus β-catenin can interact with the transcription factors from TCF/LEF1 family 
to regulate WNT dependent gene expression. While non-vertebrates like Drosophila 
melanogaster or Caenorrhabditis elegans have only one transcriptionfactor ortholog, 
chordates carry at least four. In homo sapiens these are TCF7 (Transcription factor 7, 
formerly known as TCF1), TCF7L1 (Transcription factor 7-like, formerly known as TCF3), 
TCF7L2 (formerly known as TCF4) and LEF1. The four transcription factors share a 53-
72 amino acids long N-terminal β-catenin binding domain, a central cysteine rich domain 
(CRD), a high mobility group domain (HMG) and a NLS. There is however one exception, 
TCF7L2-N a shorter isoform of TCFL2 lacks the HMG and the NLS. The TCF/LEF1 
transcription factors bind to the nuclear DNA (Deoxyribonucleic acid) via their highly 
conserved HMG domain. The binding sequence, the so-called WNT response element 
(WRE) (CCTTTGWWW), is conserved within the protein family. Several experiments 
concluded that specific mutations in the HMG domain dramatically decreased the DNA 
binding capacities of TCF/LEF1 transcription factors (Giese et al., 1991).  
DNA bound TCF/LEF transcription factors can have an activating or repressing function 
on their target genes. In the absence of β-catenin the co-repressor TLE can bind to the 
CRD domains and recruit HDACs which silence the gene expression (see Figure 4) 
(Brantjes et al., 2001; Cavallo et al., 1998; Chen et al., 1999). In the presence of β-catenin 
TLE is displaced from the transcription factor and co-activators like the histone 
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acetyltransferase CBP are recruited to induce target gene expression (Hecht et al., 2000). 
Until today a great variety of regulators of the TCF/LEF transcription complex have been 
identified. The NLK, for example, phosphorylates TCFs and hampers their ability to bind 
β-catenin (Ishitani et al., 1999, 2003).  
The diversity of function between all members of the TCF/LEF1 protein family is large, 
despite the fact that they’re highly conserved and share a common DNA binding 
sequence. Experiments with Xenopous leavis, for example, have shown that LEF1 and 
TCFL1 have tissue specific functions downstream of the canonical WNT signaling (Roël 
et al., 2002). This individual functions are attributed to structural differences, different 
isoforms and/or to certain interactions. The following Table 1 lists exemplary known WNT 
target genes with a general description of the gene function. 
 
Table 1 WNT target genes (modifed after Roel Nusse)  
Gene Organism/ 
Tissue 
Up/ 
Down* 
Function Reference 
c-myc human 
colon 
cancer 
Up Cell cycle, Apoptosis, 
Transformation 
(He et al., 1998) 
Cyclin D human 
colon 
cancer  
Up Cell cycle, Transformation (Shtutman et al., 
1999; Tetsu and 
McCormick, 1999) 
Axin2 human 
colon 
cancer 
Up Tumor suppressor, neg. WNT-
regulator 
(Yan et al., 2001) 
CD44 human 
colon 
cancer 
Up Cell-cell interactions, migration (Wielenga et al., 
1999) 
Sox9 Intestine Down Co-activator (Blache et al., 
2004) 
Cdx1 Mouse 
embryo 
Up Transcriptionfactor, neg. WNT-
regulator 
(Pilon et al., 2007) 
LEF1 
 
human 
colon 
cancer 
Up Transcriptionfactor (Hovanes et al., 
2000) 
* Effect of active WNT signaling on gene expression 
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2.4.1 The transcription factor LEF1 
Of the four human TCF/LEF family members LEF1 is of special interest for this work. The 
gene lef1 was discovered in 1991 in murine lymphocytes and was identified to propagate 
expression in the TCRα enhancer (Travis et al., 1991). In humans four relevant different 
isoforms have been described and three in mice. Figure 6 depicts a general LEF1 
structure.    
 
Figure 6 LEF1 general structure. The canonical LEF1 sequence (top) includes a β-catenin binding domain, a 
CRD domain, an HMG domain and a NLS sequence. Several different isoforms are known (indicated by boxes), 
the LEF1ΔN isoform misses the β-catenin binding domain. C-terminal B and N sequences exist in certain 
isoforms.  
 
Apart from the LEF1 canonical sequence, which codes for a 44 kDa protein, also a shorter 
isoform without β-catenin binding domain has been described (Hovanes et al., 2000). This 
isoform is also called LEF1ΔN or LEF1DN (DN=dominant negative) and lacks the β-
catenin binding domain (see Figure 6). It is thought to inhibit LEF1 dependent expression 
in most cases (Li et al., 2006). The β-catenin/LEF1 interaction was first shown in 2004, by 
precipitation of murine β-catenin with a human LEF1 bait (Hamada and Bienz, 2004). 
Apart from the interaction with β-catenin several other regulators are known to interact 
with the transcription factor. The following table lists some of these and their effect on 
LEF1 dependent gene expression (see Table 2).   
Together with its interaction partners LEF1 regulates a plethora of genes and this 
regulation largely depends on the context of the transcription factor. Only few LEF1 
specific genes like CDX1 were identified (Hecht and Stemmler, 2003). Nevertheless, the 
transcriptionfactor plays a pivotal role in many biological processes like cell differentiation. 
One example comes from osteoblasts. When LEF1 is artificially over-expressed in pre-
osteoblasts, these cells do not undergo differentiation (Kahler et al., 2006).  
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Table 2 LEF1 interaction partners 
Protein Specificity Domain Function  Reference 
β-catenin TCF/LEF1 β-catenin Activator  (Behrens et al., 1996) 
γ-catenin TCF/LEF1 β-catenin Activator  (Maeda et al., 2004) 
TLE1 TCF/LEF1 CRD Inhibtior  (Levanon et al., 1998) 
PIXT2 TCF/LEF1 Outside β-catenin 
domain 
Activator  (Vadlamudi et al., 2005) 
RUNX2 LEF1 unknown Repressed by 
LEF1 
 (Kahler and Westendorf, 
2003) 
NOTCH1 LEF1 HMG Activator  (Ross and Kadesch, 2001) 
SMADs TCF/LEF1 HMG Inhibitor/Activator  (Cui et al., 2005; Labbé et 
al., 2000) 
      
 
LEF1 mouse models 
To study the function of LEF1 in mammals several mouse models have been devised. 
First insight into the importance of LEF1 for mammalian development came from knock-
out (KO) experiments in 1994. Van Genderen and colleagues showed that a homozygous 
KO of LEF1 caused postnatal death in mice (van Genderen et al., 1994). The mice were 
deficient of teeth, body hair and mammary glands. Additionally the mice showed 
abnormalities in neurons derived in the neuronal crest. These were devoid of the 
mesencephalic nucleus. From this experiments it was clear that LEF1 is important for hair 
development and in 1995 Zhou and colleagues used knock-in methods to introduce the 
human LEF1 gene downstream of the K14 (keratinocyte 14) promoter. The promoter is 
active in basal epidermis and the outer root sheath of hair follicles. K14 driven LEF1 
expression disrupted the normally uniform orientation of hair and whiskers (Zhou et al., 
1995). The mice also developed abnormal tooth and hair growth in their mouth and gums. 
In 2002 Kratochwil and colleagues showed, again using a loss-of function model, that 
FGF4, which is a direct target of LEF1 dependent gene expression, is able to rescue the 
arrest of tooth organogenesis known from homozygous LEF1 null mice (Kratochwil et al., 
2002). However the LEF1 null mice did not show comparable phenotypes to WNT null 
mice. In 1999 Galceran and colleagues showed that this might be due to functional 
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redundancy between LEF1 and TCF7 as only a double null mutant could copy the 
phenotype of WNT3a null mice (Galceran et al., 1999). Additional insight into LEF1 
function in mammalian development came from experiments with mice expressing a 
LEF1-β-galactosidase fusion protein. The β-galactosidase herby disrupts the ability of the 
protein to bind to DNA, but its β-catenin binding domain remains functional. Mice with 
homozygous LEF1-β-gal transgene showed several developmental abnormalities, like 
strong deformation of the rib cage bone structure, as well as defects in the hippocampus 
that are also described for the LEF null mutants (Galceran et al., 2004). The knock-out 
experiments also showed an influence of LEF1 on lymphopoiesis. During B cell 
development LEF1 is only expressed in an early stadium in the bone marrow (BM), the 
absence of LEF1 in this stadium decreased the sensitivity of the cells towards WNT 
stimulation, which reduced their survival and proliferation (Reya et al., 2000).  
 
LEF1 in disease 
The transcription factor is suggested to play an important role in several diseases, 
especially in several neoplasia. The first report of LEF1 contributing to mammalian cell 
transformation came from experiments with different β-catenin mutants in colon cancer 
cell lines like 293. These experiments showed that LEF1 contributes to the oncogenic 
effect of constitutive activation of the WNT/β-catenin pathway (Porfiri et al., 1997). Later 
studies revealed LEF1 to be overexpressed in many different tumors like brain cancer, 
testicular cancer or breast cancer (Wang et al., 2005). Apart from the carcinomas also 
hematologic diseases are often reported for deregulated expression of LEF1, for example 
in ALL (Acute Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia) and CLL 
(Chronic Lymphocytic leukemia). For example in AML LEF1 expression appears to be a 
tumor driver, as transduced hematopoietic stem cells (HSCs) expressing LEF1, induce a 
AML or an ALL like neoplasia in mice (Petropoulos et al., 2008). Surprisingly, the survival 
of mice transduced with a fusion protein of LEF1 and β-catenin, which can be described 
as a constitutive active mutant, was 60 days longer when compared to animals 
transplanted with HSCs expressing full length LEF1 (310d vs 377d). This indicates that 
the aggressiveness is not completely dependent on WNT/β-catenin activity. Additionally 
Petropoulos and co-workers were able to transplant leukemic cells to wild type mice, 
which again led to a leukemic disease (Petropoulos et al., 2008). This showed that the 
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intrinsic alterations of the leukemic cells are self-sufficient. An example for a B cell 
leukemia associated with LEF1 is the chronic lymphocytic leukemia (CLL). Microarray 
studies revealed a strong up-regulation of lef1 in leukemic cells compared to healthy 
counterparts (Klein et al., 2001). Additionally Lu and colleagues showed that CLL cell 
survival can be enhanced by β-catenin stabilization (Lu et al., 2004b). Also in regard of 
this knowledge, Felix Erdfelder and co-workers analyzed the expression of lef1 in 112 CLL 
samples. They were able to show that lef1 expression is up-regulated by a factor of 80 in 
CLL cells and that its expression correlates with the disease progression and poor 
prognosis (Erdfelder et al., 2010). Later in 2010 lef1 knock-out experiments in CLL cells 
confirmed the survival enhancing properties of the transcription factor (Gutierrez et al., 
2010a). In this work, it was reported that LEF1 is also overexpressed in monoclonal B cell 
lymphocytosis, which is a preleukemic disease that can evolve into CLL. This indicates 
that increased LEF1 expression might be an early event in CLL leukemonogenesis. 
Recent meta-analysis of genome wide searches also revealed the LEF1 loci as an 
additional risk associated loci for the disease (Berndt et al., 2013). 
 
2.4.2 WNT pathway crosstalk 
Signaling pathway crosstalk is a frequent event since multiple pathways are often needed 
to integrate information. The WNT/β-catenin pathway is the focus of this work and the 
following chapter will describe the most important interactions with other pathways or WNT 
signaling branches.  
As already mentioned, several examples are known for inhibition of the WNT/β-catenin 
signaling by non-canonical WNT signaling. For example binding of WNT5a to ROR2 can 
inhibit β-catenin dependent WNT signaling (Mikels and Nusse, 2006). The concepts of 
this inhibition are unknown, but seems to rely on receptor context. Better established is 
the inhibition of WNT/β-catenin signaling by WNT/Ca2+. Upon stimulation with WNT5a the 
signal is transduced via the MAPK pathway member TAK1. This activates the NLK which 
subsequently inhibits the WNT/β-pathway by phosphorylation of its downstream 
transcription factors (see Figure 7) (Ishitani et al., 2003).  
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Figure 7 Exemplary WNT/β-catenin pathway crosstalk. On the left side the WNT/Ca2+ is activated, which in term 
leads to MAPK signaling. Subsequently NLK becomes activated and inhibits the WNT downstream transcription 
factors. In the center NOTCH1 binds to a ligand and the NOTCH1 intracellular domain is truncated from the 
receptor. This NOTCH ICD enters the nucleus and transactivates the LEF1&TCF transcriptionfactors. WNT/β-
catenin signaling leads to expression of GLI3, which can inhibit sonic hedgehog signaling. Designed with 
motifolio objects.    
Another important pathway closely associated with the WNT/β-catenin signaling pathway 
is the sonic hedgehog pathway (SHH) (see Figure 7). This pathway is, among other 
functions, essential for mammalian organogenesis. In a model developed by Ulloa and 
Marti WNT antagonizes the morphogenic effect of Shh by inducing Gli3 expression during 
dorso-ventral patterning of the vertebrate neural tube (reviewed in Ulloa and Martí, 2010).  
Direct interaction between WNT/β-catenin signaling is described for the Notch signaling 
pathway. The intracellular domain of Notch1 was shown to directly interact with LEF1 
(Ross and Kadesch, 2001). This interaction induced LEF1 dependent expression of target 
genes. The interaction between the two pathways is especially important for stem cell 
(SC) renewal and cancer. Experiments have shown that overexpression of Notch1 in 
hematopoietic progenitor cells leads to a multipotent cell line, which can give rise to 
lymphocytes as well as myelocytes (Varnum-Finney et al., 2000). The WNT signaling 
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pathway is also involved in hematopoietic stem cell renewal and necessary for maintaining 
an undifferentiated state (Reya et al., 2003). Both signaling pathways are linked as in vivo 
and in vitro experiments revealed in 2005. Duncan and colleagues generated mice with 
WNT and Notch activity reporter and isolated HSCs from these mice. Analysis showed an 
overlapping activity for most HSCs. Additionally, they were able to show that stimulation 
by WNT3a also increased Notch dependent target gene expression in this model (Duncan 
et al., 2005).  
 
2.4.3 WNT Signaling in Stem cells  
As already indicated in the previous chapter, the WNT signaling pathway is a major player 
in stem cells (SC). This chapter will combine the physiological function of WNT signaling 
in SCs with their role in cancer, as these are often similar. Experiments with murine SCs 
showed that WNT stimulation in combination with the cytokine LIF is able to maintain SC 
pluripotency without additional co-factors, while inhibition of the pathway inhibited growth 
(ten Berge et al., 2011). Interestingly β-catenin appears not to be required for evasion of 
differentiation (Lyashenko et al., 2011). In human stem cells the WNT/β-catenin signaling 
pathway appears to play a quite different role. The activation of the pathway rather leads 
to differentiation, therefore inhibition by OCT4 is needed for stem cell renewal (Davidson 
et al., 2012). Another group of pluripotent stem cells controlled by WNT signaling are the 
hematopoietic stem cells. These cells give rise to all blood cells and the WNT/β-catenin 
pathway controls their self-renewal and differentiation. The hematopoiesis with special 
regard to the development of B cells is the topic of the following chapters. 
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2.5 Hematopoiesis 
Hematopoiesis describes the process of differentiation and expansion of blood cells like 
erythrocytes or B cells. The development of all blood cells starts with the pluripotent 
hematopoietic stem cells (HSCs) which reside in the bone marrow (BM). The cells have 
the ability for self-renewal and to differentiate into many different specialized cell types. In 
the hematopoietic system two different lineage choices are discerned, the myeloid and 
the lymphoid. The myeloid lineage gives rise to cells like erythrocytes, thrombocytes, mast 
cells, neutrophils and monocytes (see Figure 8). 
 
Figure 8 Schematic overview of hematopoiesis. All blood cells originate from hematopoietic stem cells, these 
follow either the path of the myeloid or the lymphoid lineage. Each lineage gives rise to distinct cell types. NK 
= Natural Killer, E = Eosinophilic, N = Neutrophilic, B = Basophilic (modified after Motifolio)
 
The lymphoid lineage leads to natural killer cells (NK), T cells and B cells. This work will 
focus on the development of the B cells.  
 
2.6 B cell development 
The B cell development starts with the HSC, which differentiates in a common lymphoid 
progenitor (CLP). During this process the stem cells gradually lose their ability for self-
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renewal and are more and more committed to their specific lineage (Link et al., 2010). The 
common lymphoid progenitor still can differentiate into B, T and NK cells. Under the 
influence of cytokines like SDF-1 and especially Interleukin-7 the CLPs can differentiate 
into pro-B cells (see Figure 9). At this stage the B cells already carry the surface marker 
CD19 (B-lymphocyte antigen 19), which is a marker for the B cell lineage. The pro-B cells 
undergo V(D)J rearrangement, a process in which the variability of the immunoglobulin 
(Ig) heavy chain is determined (Ramsden et al., 2010). Out of several (V)ariable, (D)iverse 
and (J)oining segments a new gene is rearranged that determines the heavy chain of the 
cell specific immunoglobulin. In the next stage of development, the now called pre-B cells 
start to express the pre-B cell receptor (pre-BCR) on their plasma membrane (see Figure 
9). In this phase the immunoglobulin light chain (LC) genes also undergo a rearrangement 
of their variable (V) and joining (J) segments (Ramsden et al., 2010). This process adds 
to the great diversity of B cell receptor (BCR) specificity. During rearrangement surrogate 
light chains are expressed to form an immature B cell receptor. The BCR maturation is 
continued and the surrogate LCs are replaced by κ or λ light chains. These immature B 
cells now carry the surface marker CD19, B220R (protein tyrosine phosphatase, receptor 
type restricted (220 kDa)), IgM, MHCII, the light chains and leave the bone marrow to 
either become transitional B cells of the B1 or the B2 type. B1 B cells reside in the 
peritoneum and can be subdivided into B1a (CD5+) (T-cell surface glycoprotein CD5) and 
B1b (CD5-). B1a cells produce antibody products that participate in the innate immune 
defense, while B1b cell function in a long-term response against bacterial 
lipopolysaccharides (LPS). The majority of B cells belong to the B2 subpopulation, which 
predominantly enter secondry lymphoid tissues like the spleen. Upon entering the 
follicular zone of the spleen, the B cells undergo an Ig class switch as they now express 
IgD class immunoglobulin on their surface (see Figure 9). 
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Figure 9 B cell development. The B cell development starts in the bone marrow with the common lymphoid 
progenitor (CLP). The cells mature into pre B cells and express CD19 and a pre B cell receptor (BCR). To the 
next stage the cell undergo V(D)J rearrangement, start to express a pro BCR. The naive b cells undergo VJ 
rearrangement and express IgM. The cells leave the bone marrow to become either B1 B cells or B2 B cells, the 
latter enter the spleen. In the spleen they undergo Ig class switch from IgMhigh IgDlow to IgDhigh IgMlow. The naïve 
B cells enter secondary lymphoid tissues where they are challenged with an antigen by an antigen presenting 
cell (APC). This induces somatic hypermutation and an isotype switch, the activated B cells either become 
memory B cells or plasma cells. Designed with motifolio objects.   
 
The cells are mature but still naïve and the follicular B cells can undergo the so called 
germinal center reaction in the secondary lymphoid tissues (see Figure 9). In this process 
the B cells are activated by antigen presenting cells (APCs) like dendritic cells. These 
activate the B cells and they undergo rapid proliferation. In a process called somatic 
hypermutation the B cells variable regions of the B cell receptor show an extremely 
increased mutation rate, which can change the affinity of the BCR to its antigen (Maul and 
Gearhart, 2010). An increased affinity in term increases the survival and by this process 
the B cells are selected. The surviving cells either become memory B cells or differentiate 
further into antibody producing plasma cells.  
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2.6.1 WNT signaling in B cell development 
Most scientific publications about the influence of WNT signaling on B cell development 
deal with the early stages from HSCs to pre-B cells (see Figure 9). Early experiments 
observed that WNT1, WNT5a and WNT10b can induce proliferation in hematopoietic 
progenitor cells in vitro (Austin et al., 1997). Similar results were obtained when human 
progenitor cells were stimulated by feeder cells transduced with WNT5a, WNT2b or 
WNT10b (Van Den Berg et al., 1998). In later experiments WNT3a was identified to 
promote self-renewal, while WNT5a increased proliferation and lineage commitment 
(Malhotra et al., 2008). If active WNT/β-catenin signaling promotes self-renewal as 
general mechanism remains unclear. When constitutive active β-catenin was transduced 
to HSCs their proliferation was extremely increased (Reya et al., 2003). Similar 
experiments in vivo led to an complete bone marrow failure (Kirstetter et al., 2006). 
However the expression of constitutive active β-catenin in HSCs makes a long-term 
culture possible while the cells still retain their pluripotency (Baba et al., 2006). 
Additional interesting insights were gained from WNT and Frizzled knock-out mouse 
models. HSCs from WNT3a defective mice, that were transplanted to wildtype mice, 
proved to be defective in their capacity for self-renewal (Luis et al., 2009). The knock-out 
of WNT5a in mice also affects the lymphopoiesis. Liang and colleagues observed in mice 
with a heterozygous WNT5a knock-out an increased proliferation of B cells (Liang et al., 
2003). The WNT5a heterozygous mice developed myeloid leukemia and B cell 
lymphomas, indicating that WNT5a acts as a tumorsuppressor in murine hematopoiesis. 
Also the knock-out of FZD9 causes severe disturbance of the B cell development. 
Ranheim and colleagues observed the depletion of pre-B cells from the bone marrow and 
an abnormal high number of plasma cells in the spleen (Ranheim et al., 2005).  
 
2.6.2 LEF1 expression during B cell development 
While we have some knowledge about the presence of WNT proteins, little is known about 
their downstream transcriptionfactors. Studies in mice and men indicate that at least 
TCF7L2 and LEF1 are differentially expressed during B cell development. Studies on 
mRNA (messenger RNA) and protein level revealed that LEF1 is only expressed in the 
early B cell stages in the bone marrow (Døsen et al., 2006; Reya et al., 2000). The work 
from Døsen and colleagues showed that LEF1 is expressed in pro- and pre-B cells, but 
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neither in progenitor nor in immature B cells. TCF7L2 in contrast is expressed in progenitor 
cells and pro-B cells, but not in later developmental stages (Døsen et al., 2006). LEF1 
expression in B cells with a mature phenotype is only reported from B cell leukemia like 
chronic lymphocytic leukemia (CLL). 
 
2.7 Chronic lymphocytic leukemia (CLL) 
The disease chronic lymphocytic leukemia is caused by an accumulation of mature but 
immunoincompetent B cells in the peripheral blood (PB) and the secondary lymphoid 
tissue of the patients. The current WHO classification states as criteria for diagnosis 
lymphocyte counts of more than 5000 cells/µl and the presence of CD5+, CD19+ and 
CD23+ (Low affinity immunoglobulin epsilon Fc receptor) B cells in the peripheral blood. 
The disease is still considered incurable and the patients often die of infections, due to 
their impaired immune system. 
 
2.7.1 Etiology 
Up-today no bona fide factor for CLL induction has been identified, but the disease 
appears to have a genetic component. Several studies showed that there can be an 
inherited risk for CLL induction (Goldin et al., 2004). The disease is only common in North 
America and Europe (Pan et al., 2002). 
  
2.7.2 Epidemiology 
CLL occurrence depends on the age, sex and as already mentioned the ethnical 
background. The median age at diagnosis is rather high with 65 years with a rising 
frequency in the later years (Dighiero et al., 1991; Montserrat and Rozman, 1995; Rozman 
and Montserrat, 1995). Women are less prone to develop the leukemia and they also have 
an overall better prognosis (Bhayat et al., 2009; Catovsky et al., 1989; Mandelli et al., 
1987). Another a risk factor is a Caucasian background, while Africans and Asians rarely 
develop CLL (Dores et al., 2007).  
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2.7.3 Diagnosis 
Frequently the first indication for CLL are unusually high lymphocyte counts in the 
peripheral blood of the patients. In blood smears these lymphocytes appear monomorphic 
with a small basophilic cytoplasma and a dense nucleus. Another hint are artefacts in the 
blood smears, caused by fractured CLL cells. To discern CLL from other malignancies 
FACS (Fluorescence-activated cell sorting) analysis are performed. CLL cells express the 
markers CD5, CD19, CD23 (Hallek et al., 2008).  
 
2.7.4 Disease progression 
The progression of CLL is quite diverse. While some patients survive several years without 
the need for treatment others die within months. Over the decades physicians have 
identified several risk factors that allow assessment of the severity of the disease. Based 
blood parameters and infiltrated organs Rai and Binet developed basic schemes for risk 
stratification. They include factors like lymphocytosis, number of lymphatic areas involved, 
anemia, thrombocytopenia and organomegalia (usually spleen and/or liver) (Binet et al., 
1981; Rai et al., 1975). These two systems usually form the basis for the prognosis. 
Additional important risk factor are the expression of CD38 (ADP-ribosyl cyclase 1) and 
ZAP70 (Tyrosine-protein kinase ZAP-70), mutational status of the major tumor supressor 
TP53, IgVH (Immunoglobulin variable heavy chain region) mutational status, 
chromosomal aberrations and proliferation indicators like Thymidinkinase activity. 
 
2.7.5 Treatment 
The current first-line therapy is based on the combination of the cytostatics fludarabine 
and cyclophosphamide with the monoclonal antibody against CD20 (rituximab). Several 
other cytostatics like bendamustin or chlorambucil are frequently implemented in the 
therapeutic regimen, but this depends largely on the aggressiveness of the disease as 
well as the fitness of the patient (Hallek, 2013). As a new treatment option the tyrosine 
kinase inhibitors emerged in the last years. The best example is ibrutinib, which primarily 
targets the bruton tyrosine kinase. The drug was successfully tested on refractory and 
relapsed CLL (Byrd et al., 2013).  
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The only curative approach for CLL is the allogenic stem cell transplantation (Gladstone 
and Fuchs, 2012). Due to high risks the treatment is only suitable for young and fit patients 
with otherwise very poor prognosis.  
 
2.7.6 Pathogenesis 
Chromosomal Aberrations 
Chromosomal aberrations are a common feature and are detectable in more than 80% of 
all CLL cases. The most frequent are the deletions on 13q (55%), deletions on 11q (18%), 
trisomy of chromosome 12 (16%) and the deletion on 17p (7%). Compared to a normal 
karyotype the del(13q) is the only one with a favorable diagnosis. All other chromosomal 
aberrations, as well as complex karyotypes, are associated with a poor prognosis (Döhner 
et al., 2000). The biggest impact have the deleltions 11q and 17p. The deletion of 
chromosome 11q affects multiple genes. The most important one appears to be ATM, an 
activator of the p53 tumor suppressor. Under physiological conditions ATM and p53 
mediate DNA repair and induction of apoptosis due to DNA damage (Austen et al., 2005). 
The deletion of 17p affects the TP53 gene directly. The loss of TP53 leads to immensely 
increased resistance to treatment and rapid disease progression. Mutations of the 
remaining allele are common, which further protects the cells from apoptosis. Patients 
with mutated or deleted TP53 genes have very poor prognosis and usually die within two 
years after diagnosis, despite extensive treatment (Döhner et al., 2000; Zenz et al., 2008).  
 
The B cell receptor 
New results in the last years have underlined the importance of the B cell receptor (BCR) 
for CLL. The B cell receptor is composed of immunoglobulin and the CD17a/b heterodimer 
(Van Noesel et al., 1992). By antigen binding the receptor activates several intracellular 
signaling cascades, which induce the proliferation and selection of the B cell (Burger, 
2012). In addition is the diversity of the BCR repertoire reduced in CLL, when compared 
to normal B cells. Frequently these BCRs in CLL are polyreactive and resemble in their 
characteristics inflammation factors. The expression of autoreactive antigens appears to 
increase the survival of the malignant cells (Caligaris-Cappio and Hamblin, 1999).  
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2.7.7 WNT signaling in CLL 
One of the hallmarks of CLL cells is the abnormal expression of LEF1. This was first 
discovered by array based screens of CLL cell mRNA (Klein et al., 2001). Three years 
later Lu and colleagues took a closer look and found that most key components of the 
WNT signaling cascade are expressed in CLL cells (Lu et al., 2004a). The work identified 
WNT3, WNT5b, WNT6, WNT10a, WNT14, WNT16 and FZD3 to be overexpressed in CLL 
cells when compared to healthy B cells. The working group also inhibited the GSK3 activity 
in primary CLL cells by SB216763, which is known to activate β-catenin dependent WNT 
signaling. This resulted in an increase of CLL cell survival in vitro, while the inhibition of 
WNT signaling by R-etodalac had the opposite effect. Over the next years evidence for 
an abnormal WNT signaling in CLL cells increased. Three studies showed abnormal 
promoter methylation of WNT inhibitors like sFRP, DKK or WIF1 (Chim et al., 2006, 2008; 
Liu et al., 2006). Another aspect might be the evasion of CLL cells from WNT inhibitors. 
Filipovich and colleagues showed that inhibitors like DKK1 are not functional due to 
changes in the expression of its interaction partner LRP6 in CLL cells (Filipovich et al., 
2010). Over the last years many studies tested the impact WNT inhibitors on primary CLL 
cells. After their initial success in inducing apoptosis in CLL cells with R-etodalac Lu and 
colleagues also tested the WNT inhibitor Ethacrynic acid (EA). As expected, the 
substance was able to induce apoptosis in primary CLL cells, too (Lu et al., 2009). 
Nevertheless it remains unclear if EA inhibits only WNT signaling in CLL cells, so 
experiments with more specificity were needed. In 2010 Gandhirajan and colleagues 
published their study which used two small molecules to inhibit β-catenin-TCF/LEF1 
interaction (Gandhirajan et al., 2010). Both substances selectively induced apoptosis in 
primary CLL cells in low micromolar concentrations, while healthy B cells remained fairly 
untouched. This study is interesting due to the higher specificity of the small molecules, 
which limits the off-target events. Razavi and co-workers tested another class of WNT 
inhibitors. The so called NO-ASAs are derivatives of the Aspirin, which were shown to 
inhibit the WNT signaling pathway (Gehrke et al., 2011b; Nath et al., 2003; Razavi et al., 
2011). The studies tested two isomers, the mNO-ASA and the pNO-ASA. The para-
isomere (pNO-ASA) effectively induced apoptosis in primary CLL cells and was 
significantly less toxic to healthy control cells. In 2011 the WNT inhibitor Salinomycin was 
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tested on primary CLL cells. This compound inhibits the phosphorylation of LRP6 and was 
shown to selectively induce apoptosis in primary CLL cells (Lu et al., 2011). The results 
from the inhibition studies show a common outcome, the inhibition of the WNT signaling 
pathway reduces the survival of primary CLL cells in vitro, which again hints to the 
importance of the WNT/β-catenin signaling for CLL cell survival. Additional evidence was 
gained from animal experiments. The Emu-TCL1 overexpresses the enhancer of BCR 
signaling TCL1 in a B cell specific manner and induces a CLL like disease in mice (Bichi 
et al., 2002). With the progression of the disease some WNT components are upregulated 
by malignant cells, like WNT16, WNT10alpha and FZD6 (Wu et al., 2009). Most 
interestingly, the disease onset is significantly postponed in a FZD6 deficient background 
in this study, which indicates that WNT signaling plays at least a supportive role in the 
disease. The first direct indication of active WNT/β-catenin signaling came from Gutierrez 
and colleagues in 2010 (Gutierrez et al., 2010b). The working group transfected primary 
CLL and healthy B cells with a WNT reporter plasmid, which revealed an abnormally 
increased activity of the pathway. This was further underlined as the expression of the 
effector transcription factor LEF1 was shown to correlate with the disease progression 
(Erdfelder et al., 2010). However the idea that the WNT/β-catenin signaling is active in 
CLL is not undisputed. In an intriguing work Tendon and colleagues stained over 50 CLL 
samples by immunohistochemistry and only detected nuclear β-catenin in 12% of the 
samples (Tandon et al., 2011). The role of LEF1, which might be the most important 
WNT/β-catenin down-stream transcription factor in CLL, is also not well understood. 
Knock-down experiments revealed a high heterogeneity in response. Shalek and co-
workers defined three groups dependent on the impact of a lef1 knock-down on the 
survival (Shalek et al., 2012). The CLL cells most sensitive to lef1 knock-down showed an 
up-regulation of myc associated genes, while polycomb and embryonic stem cell genes 
were down-regulated. In CLL cells with low sensitivity to the silencing, the effect on the 
different gene groups was found to be inversed. New data suggests that the activation by 
β-catenin might be dispensable in many leukemia and that other transactivators like ATF2 
might fill this gap (Grumolato et al., 2013).  
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2.8 NO-ASAs 
Acetylsalicylic acid (ASA) is the most famous compound in modern medicine. Additionally 
to its use as painkiller, it is also reported to have an anti-cancer effect (Kashfi and Rigas, 
2005). Unfortunately is the application of ASA limited by the induction of severe side-
effects, mostly gastrointestinal, which occur when it is given for long-term and in large 
quantities. To overcome these problems NO-donating acetylsalicylic acids were 
developed. These drugs are composed of a traditional acetylsalicylic acid molecule that 
is linked via a spacer to an NO-donating moiety, which has a gastroprotective effect.  
Surprisingly, NO-ASAs proved far more effective in preventing growth of tumor cell lines 
than ASA itself, implying that either the NO donating group or the spacer possesses anti-
cancer properties. However, a limitation in all studies dealing with NO-ASA is the 
determination of the "active" part of the compound which is responsible for the 
antineoplastic effect. During metabolisation, the NO-group, the spacer and the ASA 
substructure are disconnected and can thus individually be biologically active. In the 
following sections, we will focus on the para- and the meta-isomers since only very little 
is known about oNO-ASA. 
Very important for the effect of each NO-ASA isoform is their metabolization which 
releases the effector substances. The metabolization of NO-ASA follows a general 
mechanism. Upon entering the organism, the NO-moiety of p- and mNO-ASA is rapidly 
released, and esterases cleave the traditional acetylsalicylic acid from the spacer 
molecule (Carini et al., 2004; Dunlap et al., 2008). The released nitric oxide was shown to 
have gastroprotective properties in vivo, while the ASA maintains its normal functionality 
as a PTGS1 inhibitor (Gresele and Momi, 2006). Additional studies showed a different 
mode of action. Depending on the position of the NO-moiety, the linker also appears to 
have a critical influence on the efficiency of the drug. Of these NO-ASA isomers, only the 
para-derivative forms quinone methides upon metabolisation (Dunlap et al., 2007).  
The different metabolisation appears to be important, since quinone forming isoforms 
were reported to be the far more potent drugs in inhibiting growth of tumor cell-lines in 
multiple studies (Dunlap et al., 2008; Nath et al., 2003, 2009). This effect is thought to be 
closely related to the quinone methides that appear to have a considerable cytotoxic 
effect, which arises from complexation of glutathiones (GSH). This can deplete the cellular 
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GSH, which is an important defence mechanism of the cells against oxidative stress and 
is critical for survival of many different types of cancers (Dunlap et al., 2008).  
Another key player in NO-ASA induced apoptosis of cancer cells might be the WNT-
signaling pathway. Several studies report that NO-ASA is capable of inhibiting TCF/β-
catenin dependent expression of target genes in colon, prostate and breast cancer cell 
lines (Kashfi and Rigas, 2005; Nath et al., 2003, 2009). Interestingly the para-isomer 
proved to be the more powerful drug when compared to mNO-ASA in suppressing the 
formation of the TCF/β-catenin complex, which might contribute to its higher efficacy (Nath 
et al., 2009). Additionally, it was shown that NO-ASAs nitrosylate the central protein of the 
WNT-cascade, β-catenin, as well as NF-κB and p53 in colon carcinoma cell lines (Williams 
et al., 2011). This posttranslational modification might explain in some part the inhibitory 
functions of the drug on the WNT- and the NF-κB signaling pathway. 
Information about pharmacokinetics, toxicity from pre-clinical and clinical studies is 
predominantly available for the meta-isomer (NCX4016). The drug proved to be safe in 
animal and human studies and caused no gastrointestinal side effects like traditional ASA 
(Fiorucci et al., 2003; Gresele and Momi, 2006). Additionally, high plasma levels were 
achieved in rats and humans (161 ng/ml after a single dose in rats). The meta-isomer was 
tested in clinical trial phase II as a protective drug against colorectal carcinomas, but the 
trials were stopped because of possible genotoxicity of its metabolite NCX4015 (Dunlap 
et al., 2008). 
The para- as well as the ortho-isomer, to our knowledge, were never put forward for 
clinical trials. Nevertheless the drug was successfully tested in several xenograft mouse 
model studies, including our own experiments, and showed no severe side-effects (Razavi 
et al., 2011; Rosetti et al., 2006). 
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2.9 Goals of the project 
This study is based on the hypotheses that (a) the transcriptionfactor LEF1 is an important 
factor in B cell maturation and can induce B cell neoplasia when overexpressed in B cells 
and (b) that newly developed NO-ASA derivatives effectively and selectively induce 
apoptosis in CLL cells with special regard to their usability in vivo. To test these 
hypotheses a targeted LEF1 overexpression mouse model is to be developed and tested 
for changes in the blood. The effect of the NO-ASA derivates is to be tested by in vitro 
and in vivo, the latter by a xenograft mouse model.  
 
The goals of this project are: 
1. Development of a new mouse model for targeted LEF1 overexpression 
a. Assessment of the oncogenic potential of LEF1 
b. Assessment of the impact of LEF1 overexpression in murine B cells on their 
development 
 
2. Development of new experimental drugs for CLL treatment 
a. Analysis if the toxicity, selectivity and their bioavailability 
b. Analysis of the mode of action 
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3 Materials 
3.1 Chemicals 
If not indicated all chemicals were purchased from Carl Roth GmbH, Karlsruhe or Sigma-
Aldrich, St. Louis, USA in per analysis quality. 
Table 3 Chemicals 
Chemical Company 
Dimethylsulfoxid (DMSO) for molecular biology Carl Roth GmbH, Karlsruhe 
Ampicillin Carl Roth GmbH, Karlsruhe 
Kanamycin Carl Roth GmbH, Karlsruhe 
Sesame oil Sigma-Aldrich, St. Louis, USA 
Bovine serum albumin (BSA) for molecular biology Carl Roth GmbH, Karlsruhe 
Gelatin from cold water fish skin 
TritonX-100 
Sigma-Aldrich, St. Louis, USA 
Carl Roth GmbH, Karlsruhe 
TWEEN20 Carl Roth GmbH, Karlsruhe 
Mitomycin C Sigma-Aldrich, St. Louis, USA 
  
 
3.2 NO-ASA derivatives 
Table 4 NO-ASA derivatives 
Name Structure IUPAC Source 
mNO-ASA 
O
O
OAc ONO2 
3-
[(nitrooxy)methyl]phenyl 
2-(acetyloxy)benzoate 
Cayman Chemical 
Company, Ann Arbor, 
USA 
pNO-ASA 
O
ONO2O
OAc  
4-
[(nitrooxy)methyl]phenyl 
2-(acetyloxy)benzoate 
Organic chemistry, 
University of Cologne* 
NOBA (B9) 
O
ONO2O
 
4-
[(nitrooxy)methyl]phenyl 
benzoate 
 
Organic chemistry, 
University of Cologne* 
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NO-Naphtyl (B12) 
O
ONO2O
 
4-
[(nitrooxy)methyl]phenyl 
naphthalene-1 
carboxylate 
 
Organic chemistry, 
University of Cologne* 
*Working group Prof. Dr. Albrecht Berkessel 
 
3.3 Media, Buffers & Solutions 
All not explicitly mentioned media, buffer or stock solutions were prepared according to 
Roche LabFAQs 3rd Edition. 
 
Alkaline-Lysis Buffer (1 l) 
NaOH (10 M) 2.5 ml 
EDTA (0.5 M) 1 M 
sterile H2O  add 1 L 
  
 
40 mM Tris-HCL (1 l) 
Tris-HCL pH 7 (1 M) 40 ml 
sterile H2O  add 1 L  
  
 
Ready-to-use buffers & solutions 
Table 5 Buffers & Solutions 
Buffer Company 
RPMI1640 w. stable Glutamine* PAA Laboratories GmbH, Cölbe 
IMDM w. stable Glutamine* PAA Laboratories GmbH, Cölbe 
DMEM w. stable Glutamine* PAA Laboratories GmbH, Cölbe 
PBS* (Phosphate buffered saline) PAA Laboratories GmbH, Cölbe 
Penicillin/Streptomycin (100x)* PAA Laboratories GmbH, Cölbe 
Trypsin/EDTA (1x)* Life Technologies GmbH, 
Darmstadt 
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2-Mercaptoethanol ( 50 mM)*  Life Technologies GmbH, 
Darmstadt 
NEAA (Non-essential amino acids) (100x)* Life Technologies GmbH, 
Darmstadt 
G418 (50 mg/ml)* Life Technologies GmbH, 
Darmstadt 
FCS (Fetal calf serum) Gold heat inactivated* PAA Laboratories GmbH, Cölbe 
Annexin-Binding Buffer (10x) BD Bioscience, San Jose, USA 
TAE (50x) Fisher Scientific, Schwerte 
NuPAGE® Transfer Buffer (20X) Life Technologies GmbH, 
Darmstadt 
NuPAGE® MES SDS Running Buffer (20X)  Life Technologies GmbH, 
Darmstadt 
NuPAGE® LDS Sample Buffer (4X)  Life Technologies GmbH, 
Darmstadt  
NuPAGE® Antioxidant Life Technologies GmbH, 
Darmstadt 
M-Per Lysis Buffer Fisher Scientific, Schwerte 
30% Paraformaldehyde methanol free Carl Roth GmbH, Karlsruhe 
*Cell culture quality  
 
 
 
 
Cell culture Media (final concentrations) 
Table 6 Cell culture media 
Medium A (Suspension cells)  Medium B (Adherent cells) 
RPMI 1640  DMEM (Glucose 4,5 g/l) 
L-Glutamine (300mg/l)  L-Glutamine (300mg/l) 
10% FCS  10% FCS 
Penicillin/Streptomycin (100.000 U/l; 
100 mg/l) 
 Penicillin/Streptomycin (100.000 U/l; 100 
mg/l) 
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Medium C (Primary human 
leucocytes) 
 Medium D (Primary mouse 
spleenocytes) 
RPMI 1640  IMDM (25 mM Hepes) 
L-Glutamine (300mg/l)  L-Glutamine (584mg/l) 
10% FCS  10% FCS 
Penicillin/Streptomycin (100.000 U/l; 
100 mg/l) 
 Penicillin/Streptomycin (100.000 U/l; 100 
mg/l) 
MEM NEAA (1 mM)  2-Mercaptoethanol (50 µM) 
  Murine IL7 10 ng/ml  
   
 
Medium E (Embryonic stem cell 
medium) 
 Freezing medium 
DMEM (Glucose 4,5 g/l)  RPMI 1640 
15% FCS  10% FCS 
L-Glutamine (300mg/l)  10% DMSO 
MEM NEAA (1 mM)   
2-Mercaptoethanol  (100 µM)   
Penicillin/Streptomycin (100.000 U/L; 
100 mg/l) 
  
LIF (107 U/ml)   
   
 
3.4 Recombinant proteins 
Table 7 Recombinant proteins 
Name Origin Cat. No. Company 
LIF Mouse L5158-5UG Sigma-Aldrich, St. Louis, USA 
WNT3a Mouse 1324-WN-002 R&D, Minneapolis, USA 
WNT5b Human 7347-WN-025 R&D, Minneapolis USA 
WNT10b Human 7196-WN-010 R&D, Minneapolis USA 
WNT11 Human 6179-WN-010 R&D, Minneapolis USA 
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3.5 Antibodies 
Table 8 Unconjugated antibodies 
Antigen Host Clone No. Company 
β-actin Mouse AC-74 A5316 Sigma-Aldrich, St. Louis, USA 
β-catenin Mouse 14 610154 BD Transduction Laboratories 
LEF1 Rabbit C12A5 2230 Cell Signaling Technology  
Axin2 Goat M20 sc-1004 Santa Cruz Biotechnology, Inc., 
Heidelberg 
     
 
 
Table 9 Conjugated antibodies 
Antigen Conjugate Host Reactivity Clone No. Company 
IgG Dylight-647 Goat Rabbit Polyclon
al 
111-
495-
144 
Jackson 
Immunoresearch, 
West Grove, USA 
IgG Cy3 
(Cyanine 3) 
Goat Mouse Polyclon
al 
715-
165-
150  
Jackson 
Immunoresearch, 
West Grove, USA 
IgG HRP Goat Mouse Poly405
3 
40530
6 
Biolegend, Fell 
IgG HRP Donk
ey 
Rabbit Poly406
4 
40640
1 
Biolegend, Fell 
CD5 Alexa Fluor 
647 
Rat Mouse 53-7.3 10061
4 
Biolegend, Fell 
CD45 Pacific Blue Rat Mouse 30-F11 10312
6 
Biolegend, Fell 
B220 PE-CF594 Rat Mouse RA3-
6B2 
56229
0 
BD Bioscience, 
San Jose, USA 
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3.6 Kits 
Table 10 Nucleic acid isolation 
Kit Cat. No. Company 
QIAGEN Plasmid Mini Kit (25) 12123 Qiagen N.V., Hilden 
QIAGEN Plasmid Midi Kit (25) 12143 Qiagen N.V., Hilden 
RNeasy Plus Mini Kit (50) 74134 Qiagen N.V., Hilden 
MinElute Gel Extraction Kit (50) 28604 Qiagen N.V., Hilden 
   
 
Table 11 Cell isolation 
Kit Cat. No. Company 
CD19 MicroBeads, human 130-050-301 Miltenyi Biotec GmbH, 
Bergisch-Gladbach  
B Cell Isolation Kit II, human 130-091-151 Miltenyi Biotec GmbH, 
Bergisch-Gladbach  
Rosette SepTM Human B  
Cell Enrichment Cocktail  
15024 STEMCELL 
Technologies SARL, Köln 
CD19 MicroBeads, mouse 130-052-201 Miltenyi Biotec GmbH, 
Bergisch-Gladbach  
CD45R (B220) MicroBeads, mouse 130-049-501 Miltenyi Biotec GmbH, 
Bergisch-Gladbach  
   
 
 
Table 12 Miscellaneous 
Kit Cat. No. Company 
SuperSignal West Pico Chemiluminescent 
Substrate 
34087 Fisher Scientific, 
Schwerte 
Mouse ES Cell Nucleofector®Kit VPH-1001 Lonza, Basel, 
Switzerland 
CellTiter-Glo® G7570 Promega, 
Mannheim 
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3.7 Miscellaneous 
 
Table 13 Competent bacteria 
Bacteria Strain Company 
NEB 5-alpha Competent E. coli 
(High Efficiency) 
DH5α New England Biolabs 
GmbH, Frankfurt am Main 
  
 
Table 14 Plasmids 
Plasmid Description 
pSTOP-EGFP-ROSA-CAGs TV* Targeting vector for murine ROSA26 locus 
with a floxed STOP cassette and EGFP 
reporter 
Size: 16056 bp 
Resistance: neo  
 
pDEST26-LEF1 Human lef1 open reading frame in pDEST26 
backbone 
Size: 8600 bp 
Resistance: amp 
*Kindly provided by the Institute for Genetics, University of Cologne 
 
 
Table 15 Enzymes 
Enzyme Type Company 
AscI Restrictionenzyme New England Biolabs 
GmbH, Frankfurt am Main 
BamHI Restrictionenzyme New England Biolabs 
GmbH, Frankfurt am Main 
AsiSI Restrictionenzyme New England Biolabs 
GmbH, Frankfurt am Main 
T4-Ligase Ligase New England Biolabs 
GmbH, Frankfurt am Main 
Pfu Polymerase Fisher Scientific, Schwerte 
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RevertAid Premium  
Reverse Transcriptase 
M-MuLV Reverse 
Transcriptase 
Fisher Scientific, Schwerte 
FastStart Taq 
DNA Polymerase 
Taq based Master mix for 
conventional PCR 
(polymerase chain 
reation) 
Roche Diagnostics 
Deutschland GmbH, 
Mannheim 
Big dye 3.1® Sequencing Master mix Life Technologies GmbH, 
Darmstadt 
   
 
3.8 Instrumentation 
Table 16 Instruments 
Instrument Type Company 
Gallios™ 
+ 488 
+ 638 
+ 405 
Cytometer 
+ Laser 
Beckman Coulter GmbH, 
Krefeld 
Axio Scope.A1 
+ AxioCam MR 
+ AxioCam ICc1 
Microscope 
+ Camera 
Carl Zeiss Microscopy 
GmbH, Göttigen 
Nucleofector 2™ Nucleofection Device Lonza, Basel, Switzerland 
MicroLumatPLUS Luminometer BERTHOLD 
TECHNOLOGIES GmbH & 
Co. KG, Bad Wildbad 
   
 
3.9 Animal housing 
The mice were housed in a separated building. The mice were kept in individually 
ventilated cages with 81 cm2 floor area (Type EURO II long) with up to five mice per cage. 
Whenever possible the mice were kept in groups of 2-5 individuals (usually littermates). 
The different genotypes were not kept separately. The mice were tagged with earmarks 
for individual identification. Breathing air was filtered (80 µm pore size) and all handling 
was performed in laminar air flow cabinet. All mice received specialized high protein 
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breeding diet (V112x-M-Z, SSNIFF, Soest) as well as acidified water add libitum. Day and 
night cycle was 12 h by 12 h without seasonal adaptation.   
 
3.10 Cell lines 
Table 17 Cell lines 
Cell line  Source Cell type Origin Features 
JVM3 German 
Collection of 
Microorganisms 
and Cell 
Cultures GmbH 
(DSMZ) 
chronic B cell 
leukemia 
Peripheral blood of 
a 73 mal with B-
prolymphocytic 
leukemia 
 
lymphoblastoid cells 
growing in clumps in 
suspension 
EBV transformed 
 
BRUCE4 Institute for 
Genetics, 
University of 
Cologne* 
Stem cell Mouse C57/BL6 Embryonic Stem cell 
ES 
Feeder 
cells 
Institute for 
Genetics, 
University of 
Cologne* 
Fibroblast Mouse C57/BL6 Mouse embryonic 
fibroblast, 
expressing LIF, 
G418 resistant 
*Kindly provided by PD Dr. F. Thomas Wunderlich, Institute for Genetics, University of Cologne 
 
All used cell lines were cultivated at 37°C with 5% CO2 and ≥90% humidity. The medium 
was chosen according to the recommendations of the DSMZ (German Collection of 
Microorganisms and Cell cultures).  
 
3.11 Software 
Table 18 Software 
Name Version Company 
Prism 5 for Windows 5.01 GraphPad Software, Inc 
   
ACD/ChemSketch (Freeware) 12.0 Advanced Chemistry 
Developement, Inc 
   
ImageJ 1.47n Wayne Rasband, National Institutes 
of Health, USA 
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Kaluza 1.2 Beckman Coulter GmbH, Krefeld 
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4 Methods 
4.1 Protein electrophoresis & Immunoblotting 
All mammalian cells used for protein electrophoresis and western blot experiments were 
lysed in M-Per lysis buffer (Thermo Scientific, Schwerte), which was supplemented with 
Protease inhibitor cocktail (Complete mini Protease inhibitor cocktail, Roche, Mannheim) 
according to manufacturer’s instruction. For all protein gel electrophoresis and western 
blot experiments the NuPAGE system of Life Technologies GmbH Darmstadt was used 
according to the provided protocols. The antibodies for immunoblotting experiments were 
used according to the provided instructions if not indicated otherwise. 
The general procedure was as follows: 
 Wash 1x membrane with TBS (Tris-buffered saline)-T (TBS + 0.1% TWEEN20) 
 Block membrane with 10% (w/v) non-fat dry milk powder or BSA in TBS-T 
 Incubate membrane with primary antibody in TBS-T + 5% non-fat dry milk powder 
or BSA overnight at 4°C 
 Wash 3x with TBS-T 
 Incubate membrane with secondary antibody in TBS-T + 5% non-fat dry milk 
powder or BSA for 2 h at RT 
 Wash 3x with TBS-T 
 Drench membrane in luminescence substrate solution 
 Detect luminescence with x-ray film 
 
4.2 Immunofluorescence 
For Immunofluorescence staining the following protocol for adherent cells was used. 
 Wash cells 3x with cold PBS 
 Fix cells with cold 4% PFA in PBS for 20 min at RT 
 Incubate cells with 0.1% TritonX-100 in PBS for 5 min 
 Wash cells 2x with PBS 
 Block with 5% normal goat serum (NGS) in PBS+0.2% Gelatin for 30 min 
 Incubate with primary antibody in PBS+2% NGS+0.2% Gelatin overnight at 4°C  
 Wash 3x with PBS+0.2% Gelatin 
46 
 
 (Optional) Incubate with secondary antibody in PBS+2% NGS+0.2% Gelatin for 2 
h at RT 
 Wash 3x with PBS+0.2% Gelatin 
 Wash 2x with PBS 
 Wash 1x with dest. H2O 
 Cover in appropriate mounting medium 
 
4.3 Cell culture 
All cell culture work was performed under sterile conditions in laminar-flow workbenches, 
which were routinely cleaned and disinfected. The different cell lines were thawed, 
cultured and stored according to the recommendations of the DSMZ (Leibniz-Institut 
DSMZ-Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, 
Braunschweig). Primary cells were frozen at 5x106 cells per ml Freezing Medium. 
 
4.4 Primary Cell isolation 
Murine lymphocytes from spleen (mSPL) 
For the isolation of murine spleenocytes the donor mice were sacrificed using cervical 
dislocation. Afterwards the spleens were isolated and homogenized by grinding through 
a sterile 70 µm mesh and suspended in PBS + 2% FCS. For removal of cellular debris 
and red blood cells the suspension is layered on Ficoll suspension (Lymphocyte 
Separation Medium 1077 from PAA) and centrifuged at 500 x g for 20 min. The Buffy coat 
is retrieved, than washed twice with PBS + 2% FCS and used freshly for experiments. For 
cultivation, cells were kept at 37°C with 5% CO2 in medium D unless indicated otherwise. 
 
Murine embryonic fibroblasts (MEFs) 
For the isolation of MEFs 13.5 day after conception the mother is sacrificed via cervical 
dislocation and the embryos are harvested. Each embryo is transferred to a 6 cm dish 
filled with PBS and all maternal tissue is removed. Afterwards it is washed twice in PBS 
by repeatedly transferring it to new culture dishes with PBS. After washing the head is cut 
of and all red organs are removed. The head can be stored for genotyping. After organ 
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removal the embryo is washed three times with PBS and then ripped apart with forceps. 
The tissue mixture is resuspended in Trypsin solution and incubated for 15 minutes at 
37°C. The resulting cell suspension is mixed 1:1 with medium B and cleared by passing 
through a 40 µM filter. Then the cell mixture can be seeded out (usually 1-2 75m2 tissue 
culture flasks).  
 
Human Chronic lymphocytic leukemia cells (CLL) 
Primary CLL cells were isolated from peripheral Blood of CLL patients using the Rosette 
SepTM Human B Cell Enrichment Cocktail (STEMCELL Technologies SARL, Cologne, 
Germany) according to the manufacturer’s recommendations. After isolation all 
experiments were started within 12 h. For cultivation cells were kept at 37°C with 5% CO2 
in medium C unless indicated otherwise. 
 
Human peripheral blood mononuclear cells (hPBMCs) 
PBMCs were isolated from the peripheral blood of healthy volunteers. Blood was collected 
and mixed with 1:1 with PBS + 2% FCS. The mixture was layered on a Ficoll suspension 
(Lymphocyte Separation Medium 1077 from PAA) and centrifuged at 1200 x g for 20 
minutes. The Buffy coat is retrieved, than washed twice with PBS + 2% FCS and used 
freshly for experiments. For cultivation cells were kept at 37°C with 5% CO2 in medium C 
unless indicated otherwise. 
 
Human B cells (hB cell) 
Where isolated from PBMCs or from dispensable cell mixtures derived from human Serum 
preparations (healthy donors). The B cells were isolated either with the CD19 microbeads 
Kit (positive selection) or the B cell isolation kit II (negative selection) (Miltenyi Biotec 
GmbH, Bergisch Gladbach, Germany) according to the manufacturer’s recommendations. 
For cultivation cells were kept at 37°C with 5% CO2 in medium C unless indicated 
otherwise. 
 
48 
 
4.5 Proliferation assay 
For the proliferation experiments freshly isolated murine leucocytes from the spleen were 
used. Cells were counted and resuspended at 1x108 cells/ml in RPMI1640 with 10% FCS. 
For staining the mSPL were incubated with 10 µM CellTrace™ Violet (Molecular probes) 
for five minutes at room temperature. After staining cells were washed three times with 
Medium D and cell viability and cell number are determined again. For experiments the 
mSPL were resuspended at 2x106 cells/ml in Medium D, seeded out on a 96-well plate 
(100 µl/well) and incubated at 37°C and 5% CO2 for 48 h with different stimulants.  
 
                  Table 19 Stimulants for B cells 
Stimulant Final concentration 
LPS 10 µg/ml 
Recombinant murine WNT3a 400 ng/ml 
Recombinant human WNT5b 1000 ng/ml 
Recombinant human WNT10b 1000 ng/ml 
Recombinant human WNT11 1000 ng/ml 
LiCl 50 mM 
  
 
After incubation cells washed once with PBS and resuspended in 50 µl Annexin V-
Bindingbuffer (BD Bioscience) and stained with CD45R-PE-CF594 (B cells) and Annexin 
V-Alexa647 (apoptotic and dead cells) according to manufacturer’s recommendations, 
than washed three times with PBS analyzed via FACS. 
 
4.6 Transgenic mice 
4.6.1 Generation of LEF1 knock-in strain 
Cloning & Transfection 
The coding mRNA sequence of LEF1 (NM_016269) was amplified from pDEST26-LEF1 
plasmid the using primers containing the AscI restriction site (LEF1 for AscI 
ggcgcgccaccatgccccaactctccggaggag & LEF1 rev AscI 
ggcgcgccctatcagatgtaggcagctgtcattcttgg).  
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Figure 10 Cloning strategy. Full length lef1 without any introns was amplified from the pDEST26-LEF1 Vector. 
AscI restriction sites were added by primer design. Lef1 was cloned via AscI into the targeting vector STOP-
EGFP-ROSA-CAGs TV. 
 
The amplicon was cloned into the Rosa26 targeting vector STOP-EGFP-ROSA-CAGs TV 
via the AscI restriction site. The construct was linearized and electroporated into C57/BL6 
derived Bruce4 cells with the Amaxa Nucleofector® system after manufacturer’s 
instructions.  
 
Embryonic stem cell culture 
Bruce4 stem cells depend on feeder cells (FCs) in order to proliferate and keep 
pluripotency. Feeder cells were expanded in Medium B and treated with Mitomycin C (10 
µg/ml) for 2.5 h, washed and frozen in DMEM + 20% FCS + 10% DMSO. Frozen cells 
were recovered one day prior use. The culture dishes were coated with gelatin prior use 
and enough FCs were seeded out to form a confluent layer of cells in the culture dish (e. 
i. 4*106 per 10 cm dish).  
ES cells were expanded prior electroporation on FCs in Medium E. Electroporated ES 
cells were again seeded on EF cells and incubated for 48 h to ensure expression of 
resistance genes. Twenty-four hours after electroporation, selection of transfected ES 
cells was started by addition of G418 (400 ng/ml). The medium was changed daily for two 
weeks to maintain pluripotency of the stem cells and selection pressure on untransfected 
ES cells. After two weeks of selection remaining ES cell colonies were collected and 
50 
 
individually cultivated and tested for transgene insertion into the ROSA26 locus by 
southern blot. Cells with insertion were expanded and put forward for injection into 
blastocysts.  
 
Injection & Germline transmission 
Stably transfected BRUCE4 cells were injected into CB20 Blastocysts (BALB/c 
background). The resulting hybrid generation was crossed with C57BL/6 mice to gain 
germline transmission with C57BL/6 background. Pups with black coat originate from 
BRUCE4 cells and were tested with specific primers for GFP (green fluorescent protein) 
and NEO (neomycin) for germline transmission of the transgene. One female was tested 
positive for GFP and NEO and founded the new transgenic strain B6;C-
Gt(ROSA26)Sortm1(lef1)Cgn.  
 
4.7 Transgenic mouse strains 
Strain: B6;C-Gt(ROSA26)Sortm1(lef1)Cgn 
Short: R26lef1 
Origin: newly established 
Features: Targeted knock-in of human lef1 cDNA (complementary DNA) Isoform1 into the 
Rosa26 locus (R26). The disruption of the Rosa26 has no known phenotype. The 
transgene is headed by a floxed STOP cassette and a CAG promoter. Mice of this strain 
do not express LEF1 without Cre recombinase activity. The strain has no obvious 
phenotype in the heterozygous or the homozygous condition and is healthy and fertile.   
 
Strain: B6.129P2(C)-Cd19tm1(cre)Cgn 
Short: CD19wt/cre 
Origin: The Jackson Laboratory 
Features: Targeted knock-in of the bacteriophage P1 Cre Recombinase gene into the 
CD19 locus. The transgene results in a replacement of CD19 expression in B cells with 
Cre recombinase. The expression is specific for B cells starting at the earliest stage of 
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development. Homozygous mice are CD19 deficient and show a reduction of B1 B cells 
and IgM Serum levels (Rickert et al., 1995). The ability to respond to T cell antigens is 
also impaired. Due to this knowledge only heterozygous (wt/cre) mice were used in this 
work, which have no known phenotype.    
 
Strain: B6.C-Tg(CMV-cre)1Cgn 
Short: CMV-cre 
Origin: The Jackson Laboratory 
Features: Carries the cre recombinase gene of the bacteriophage P1 under the control of 
the CMV (Cytomegalovirus) promoter. The strain is used as efficient deleter strain for 
floxed sequences virtually every tissue starting with early embryogenesis. While the 
insertion site is unknown the strain exhibits no known phenotype.   
 
Strain: B6.Cg-Tg(Cr2-cre)3Cgn/J 
Short: Cr2-cre 
Origin: The Jackson Laboratory 
Features: Expression of Cre recombinase under control of Cr2-Promoter. Cr2 dependent 
Cre expression is started in transitional B cells. Heterozygous mice have no obvious 
phenotype.  
 
Strain: CB17.Cg-PrkdcscidLystbg-J 
Short: SCID beige 
Origin: Charles River 
Features: These strain carry mutations in the Prkdc and the Lyst gene. Homozygous 
Prkdc mutation in addition to Lyst gene mutation results in underdeveloped lymphatic 
tissue, severe B and T cell dysfunction, NK cell deficiency and lymphopenia. Because of 
its impaired lymphatic cells this strain is suited for xenograft experiments. In contrast to 
other immunodeficient mouse models this strain is not nude.   
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4.7.1 Genotyping 
Identification of the different genotypes is essential for analysis. The genetic material of 
the pups was retrieved by cutting the tip (1 mm) of the tail. The tail tissue was transferred 
to a 1.5 ml reaction tube and covered with 100 µl of Alkaline-Lysis Buffer and incubated 
at 95°C for 1 h. After cooling 100 µl 40 mM Tris-HCl were mixed with the reaction. 
Afterwards the reaction was centrifuged at 10,000 x g and 2 µl were used for every PCR. 
 
Table 20 Genotyping Mastermix 
PCR Genotyping mix  
PCR Master Mix (2x) 10 µl 
Forward Primer (10 µM) 1 µl 
Reverse Primer (10 µM) 1 µl 
Template 2 µl 
H2O (PRC grade) 6 µl 
Total 20 µl 
 
For each Genotype different primer sets were used: 
Table 21 Primer Genotyping 
Genotype Primer Sequence 5‘-3‘ Target Amplicon 
size 
R26 tm1(lef1)Cgn oIMR8545
* 
AAAGTCGCTCTGAGTT
GTTAT 
Common  
 oIMR8052
* 
GCGAAGAGTTTGTCCT
CAACC 
Mutant    340 bp 
 oIMR8546
* 
GGAGCGGGAGAAATG
GATATG 
Wildtype    650 bp 
     
Cd19tm1(cre)Cgn CD19c† AACCAGTCAACACCCT
TCC 
Common  
 CD19d† CCAGACTAGATACAGA
CCAG 
Wildtype    452 bp 
 Cre7† TCAGCTACACCAGAGA
CG 
Mutant ≈ 700 bp 
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Tg(CMV-
cre)1Cgn 
oIMR1084
* 
GCGGTCTGGCAGTAAA
AACTATC 
Mutant  
 oIMR1085
* 
GTGAAACAGCATTGCT
GTCACTT 
Mutant ≈ 100 bp 
     
B6.Cg-Tg(Cr2 
cre) 
oIMR1084
* 
GCGGTCTGGCAGTAAA
AACTATC 
Mutant  
3Cgn/J oIMR1085
* 
GTGAAACAGCATTGCT
GTCACTT 
Mutant ≈ 100 bp 
     
* The Jackson Laboratory Genotyping Protocols 
† Kristen M., et. al. Deletion of genes encoding PU.1 and Spi-B in B cells impairs differentiation 
and induces pre-B cell acute lymphoblastic leukemia. Blood. 118(10):2801-8 
 
Table 22 Protocol Thermocycling 
Step Temperature Time Repeats 
1 95 °C 15 min  
2 95 °C 20 sec  
3 55 °C 20 sec  
4 72 °C 45 sec 2-4 35x 
5 72 °C 5 min  
6 8°C ∞  
    
 
 
 
4.8 Analysis of murine peripheral blood 
4.8.1 Blood counts 
The peripheral blood of LEF1 expressing and reference mice was drawn from the tail vein 
via a small incision every eight weeks. The blood was instantly mixed with heparin for anti-
coagulation and analyzed within 12 h. For complete blood counts 15 µl blood were mixed 
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1:1 with Diluent, Ac•T PAK (Beckman Coulter GmbH) and subsequently analyzed with the 
COULTER® Ac·T diff2™ (Beckman Coulter GmbH).  
 
4.8.2 FACS 
For FACS analysis the 40 µl of peripheral blood were used. The blood was mixed with the 
following antibody combination and incubated in the dark for 15 minutes: 
 CD45-Pacific Blue (Biolegend) 
 CD45R (B220)-PE-CF594 (BD Bioscience) 
 CD5-Alexa647 (Biolegend) 
Afterwards the red blood cells were removed with RBC lysis buffer (eBioScience, San 
Diego, USA) according to manufacturer’s instructions and washed twice with PBS. The 
remaining leucocytes were analyzed with a ten color NAVIOSTM (Beckman Coulter GmbH) 
with the following gating strategy (see Figure 11). In the first step CD45 is plotted vs. the 
sideward scatter signal to distinguish leucocytes (CD45+) from red blood cells and debris 
(CD45-). In a second step the population that contains predominantly lymphocytes 
(CD45+, SSlow) is gated [Lymphocytes]. Ongoing from this population the percentage of B 
cells (B220++) and the T cells (CD5+) are calculated.  
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Figure 11 Gating strategy. Peripheral blood and bone marrow sample were stainend with CD45-Pacific Blue 
(Biolegend) CD45R-PE-CF594 (BD Bioscience) and CD5-Alexa647 (Biolegend). Upper left panel depicts the 
sideward scatter vs. CD45 and allows gating of the lymphocyte population. Upper right panel depicts the GFP 
expression (in this case negative). The lower panels show the exemplary gating of B (right) and T cells (left) in 
the lymphocyte population.  
 
4.9 SCID beige Xenograft mouse model 
To test different experimental therapies xenograft animal models are commonly used. In 
this project human derived JVM3 cells are injected into SCID beige mice. The JVM3 cells 
thereby are a model for malignant B cells while the SCID beige mice provide the growth 
of the tumor.  
 
Cell culture and injection 
The JVM3 cells are expanded in Medium A according to the instructions of the DMSZ for 
this cell line. For this experiment only JVM3 cells under passage number 12 (after receipt 
from the DSMZ) were used for injection. The cells were washed twice with PBS, counted 
and adjusted to 1x108 cells/ml in PBS. The cell suspension then was injected within 1 h 
subcutaneously into the right flank of 8 weeks old SCID beige mice (1x107 cells per 
mouse). After injection the tumor growth was checked every other day by caliper. The 
tumorvolume was approximated with the following formula: 
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𝑉𝑜𝑙𝑢𝑚𝑒 ≈  𝐿𝑒𝑛𝑔𝑡ℎ × (
1
2
× 𝑊𝑖𝑑𝑡ℎ2 ) 
 
Experimental therapy 
The experimental treatment for each mouse was started individually when palpable and 
evidently growing tumors with a volume of 50-100 mm3 were observed. The separation 
into different treatment regimens was achieved by dice until each group contained the 
desired number of individuals. For treatment the mice received an experimental drug 
solved in sesame oil or the oil alone as vehicle control via intraperitoneal injection every 
other day. The growth of the tumor was checked under treatment for 21 days every second 
day as described earlier.  
 
4.10 mRNA Expression array 
Human CLL cells (1x107 cells/ml) were incubated for 24 h with DMSO, pNO-ASA and 
mNO-ASA. After incubation the cells were washed and total RNA (Ribonucleic acid) was 
isolated with the RNeasy Plus Kit (Qiagen, Hilden) after the manufacturer’s instructions. 
The RNA was analyzed by ServiceXS B.V. (Leiden, Netherlands) using the Illumina 
Human HT12 chips. Data analysis was performed with dChip software with the following 
criteria p ≤ 0.05, foldchange ≤ 2.00 and difference of means ≤ 200.00. Genes considered 
to be significantly altered were used for heatmap generation, the results are clustered by 
treatment. Data annotation analysis of the significantly altered genes was performed with 
the online tool DAVID (Database for Annotation, Visualization and Integrated Discovery) 
(http://david.abcc.ncifcrf.gov/home.jsp). 
 
4.11 Declarations 
All animal experiments were authorized by the local authorities (File No. 8.87-
50.10.37.09.299 &. 87-51.04.2010.A366). All material from human donors was acquired 
according to the rules of the World Medical Association Declaration of Helsinki (6th 
revision, Seoul, Southkorea, 2008) and were authorized by an ethics committee (No. 11-
319).  
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5 Results 
 
5.1 The R26lef1 mouse strain 
5.1.1 Development and founder mouse 
After transfection and selection of BRUCE4 stem cells the insertion of the target plasmid 
into the ROSA26 locus was verified via southern-blot (performed by the Lab of Thomas 
Wunderlich) and the inserted transgene LEF1 cDNA was sequenced from gDNA samples. 
The results showed positive integration into the ROSA26 locus and 100% sequence 
identity to CCDS3679.1. After injection of stem cells into blastocysts a total of six mice 
with mixed background (hybrid generation) were born in February 2010. This hybrid 
generation was crossed with C57BL/6 mice and transgene transmission was achieved in 
one founder mouse in February 2011, confirmed by PCR for gfp, neo and cre. In the 
following text R26lef1 refers to homo- or heterozygous mice carrying the transgenic LEF1 
allel. Additional transgenic cre recombinase expression are either refered to as CMV-cre, 
Cr2-cre or CD19wt/cre, of which only the latter discerns between heterozygous and 
homozygous mice. In CD19wt/cre mice the Cre recombinase expression is controlled by the 
CD19 promotor (pan-B cell), in Cr2-cre by the CD21 promotor (transitional B cells) and in 
CMV-cre by the CMV promotor (ubiquitous). 
 
5.1.2 Cre activity induces LEF1 overexpression 
To induce transgene expression R26lef1 mice were crossed with CD19wt/cre (pan-B cell), 
CMV-cre (ubiquitous) and Cr2-cre (transitional B cells) mice, which express the cre 
recombinase gene in different tissues and developmental stages. The activity of the Cre 
recombinase was tested in R26lef1 CD19wt/cre mice and was first detected by expression 
of the GFP reporter via FACS (see Figure 12). In average about 76% (Range: 94-35%, 
n=30; 8 weeks) of the B220 positive cells in the peripheral blood were tested positive for 
the reporter protein. This is an about 20% lower efficacy than it was described by Demircik 
and coworkers for the CD19-cre strain (Demircik et al., 2013) 
58 
 
 
Figure 12 GFP is expressed in peripheral blood B cells of R26lef CD19wt/cre mice. Lymphocytes from the 
peripheral blood of R26lef1 (control) and R26lef CD19wt/cre mice were stained with anti-CD45-PacificBlue and anti-
B220-PE-CF594 antibodies. The figure shows representative examples of two littermates.  
 
Virtually no GFP expression was detected in non B cells from the peripheral blood, the 
bone marrow or the spleen. Over the monitoring period no changes in reporter gene 
expression was detected, and the expression remained stable for up to 18 months. Figure 
13 shows exemplary the MFI (Mean fluorescent intensity) of GFP expressing cells over 
the term of 48 weeks, which remains constant for the GFP positive population. 
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Figure 13 Exemplary reporter GFP expression remains stable over 48 weeks. The mean fluorescence intensity 
of GFP expressing cells in lymphocyte population of mouse 678 (R26lef1 CD19wt/cre) was measured via flow 
cytometry after 16, 32 and 48 weeks.  
 
In R26lef1 CMV-cre mice the pattern of GFP expressing cells was substantially different. 
In average 50.7% (Range: 22.0-78.5%, n = 20; 8 weeks) of the lymphocytes expressed 
the reporter protein. The average percentage of positive cells in eight week old mice was 
60.0% in the B cell (Range: 24.2-97.0%) and 36% in the T cell population (Range: 10.3-
77.4%) (data not shown). 
The GFP expression in the peripheral blood of R26lef1 Cr2-cre mice was restricted to B220 
positive B cells. Of the B220 positive cells approximately 80% (n = 6; 40 weeks) expressed 
GFP.   
To test whether Cre activity also induces LEF1 expression in isolated B cells from the 
spleen was tested by immunoblot analysis. Figure 14 shows exemplary results for animals 
from two different litters at the age of two and five month. In both cases LEF1 was 
overexpressed in the R26lef1 CD19wt/cre strain when compared to R26lef1 mice, which 
served as control (see Figure 14).  
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Figure 14 LEF1 expression in murine B cells. Immunoblot analysis of LEF1 expression in CD19 selected B cells 
from the spleen. The LEF1 expression of two mates from two independent litters (two and five months old), 
each lane represents one individual (R26lef1 CD19wt/cre (left) and R26lef1 (right)). 
 
Figure 14 shows a distinct overexpression of LEF1 in R26lef1 CD19wt/cre. While the antibody 
also detects endogenous protein in control mice, the levels appeared to be increased, at 
least five fold, in mice with Cre activity. 
In order to test for subcellular localization of overexpressed LEF1, mouse embryonic 
fibroblasts (MEFs) with different genetic backgrounds were generated. Figure 15 shows 
a considerable overexpression of LEF1 in MEFs with R26lef1 CMV-Cre background. The 
LEF1 is hereby almost exclusively localized in the nucleus. Some R26lef1 CMV-Cre cells 
however did not seem to express LEF1. The MEFs without any Cre activity expressed 
only background levels of LEF1. β-catenin was strongly expressed in MEFs from all 
strains. It was predominantly localized at the plasma membrane with rare translocation to 
the nucleus.  
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Figure 15 LEF1 expression in MEFs. Immunofluorescence analysis of murine embryonic fibroblasts (MEFs). 
MEFs from an R26lef1 and from an R26lef1 CMV-Cre were fixed and stained for LEF1 (anti-LEF1 (C12A5)) and β-
catenin (anti-β-catenin (14)) and with the corresponding secondary antibodies anti-rabbit DyLight647 and anti-
mouse Cy3. Pictures show the exemplary results from two siblings.  
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5.1.3 WNT activation leads to increases number of cells with nuclear Axin2  
To test whether the transgene influences the WNT signaling pathway 
immunofluorescence staining of MEFs with R26lef1CMV-cre background were prepared. 
This experiment was conducted to clarify if artificial LEF1 expression affects the 
subcellular localization of Axin2. This was tested in unstimulated as well as in MEFs 
stimulated with the WNT activator LiCl. Figure 16 shows the exemplary expression of 
LEF1 and Axin2 in this model. Cells that were regarded as positive for LEF1 expression 
are indicated with arrows. 
 
 
Figure 16 LEF1 and Axin2 expression in R26lef1 CMV-cre MEFs treated with 20 mM LiCl for 16 h. MEFs with 
R26lef1 CMV-cre background were cultivated for 24 h on glass slides. Then the cells were treated with 20 mM 
LiCl for 16 h. After the treatment period cells were fixed with PFA and stained for LEF1 (C12A5) and Axin2 (M20).  
As secondary antibodies anti-rabbit DyLight647 and anti-mouse Cy3 were used. Arrows indicate LEF1 
expressing cells with nuclear Axin2. Arrows indicate two exemplary cells with transgenic LEF1 expression and 
nuclear localization of Axin2.  
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Figure 16 shows a distinct localization pattern of Axin2 in LEF1 overexpressing cells. In 
the absence of any stimulation of the WNT signaling pathway, few cells had detectable 
nuclear Axin2. A strong WNT stimulation by LiCl treatment increased the total abundance 
of cells with nuclear Axin2. The total difference in number between both genotypes 
remained comparable between treated and untreated cells. Figure 17 shows the number 
of cells that exhibit nuclear Axin2 in dependence on LiCl treatment and LEF1 expression. 
 
Figure 17 Analysis of Axin2 subcellular localization in MEFs. MEFs from three different individuals with R26lef1 
CMV-cre background were cultivated on glass slides for 24 h prior treatment. After 16 h of treatment with 20 
mM of LiCl the cells were fixed and stained for LEF1 (C12A5), Axin2 (M20) and DAPI. As secondary antibodies 
anti-rabbit DyLight647 and anti-mouse Cy3 were used. Nuclei with distinct LEF1 and Axin2 expression like in 
Figure 16 indicated by arrows were considered as LEF1 positive cells with nuclear Axin2.  
 
As expected LiCl increased WNT stimulation the percentage of cells with nuclear Axin2 in 
LEF1 positive and negative cells. The percentage rose in LEF+ cells from 25.4% to 58.3% 
and in LEF1- cells from 2.7% to 28.1%. Therefore both groups showed an increase of 
about 23%. The percentage of cells with nuclear Axin2 was increased in LEF1 
overexpressing cells, with 24.4% vs. 2.7% in untreated and 58.3 vs. 28.1% in LiCl treated 
samples. 
 
5.2 Phenotype of R26lef1 CD19wt/cre mice 
The R26lef1 CD19wt/cre was created by mating the founder mouse of the R26lef1 strain with 
CD19wt/cre mice (a gift from Dr. Nina Reinart, University of Cologne) and became the first 
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strain with transgenic LEF1 expression. For all following experiments heterozygous 
CD19wt/cre mice, confirmed by PCR, were used, since homozygous mice have severe 
defects in their B cell development (Rickert et al., 1995). The mice for the subsequent 
experiments were bred from April 2011 to July 2012. A total of 65 R26lef1 and 58 R26lef1 
CD19wt/cre mice were monitored for a mean period of 11.89 and 12.72 months respectively 
(see Table 23). The transgene expressing mice population showed a slight bias towards 
males, whereas the control population was nearly balanced.  
 
Table 23 Population statistics and disease related deaths (animals sacrifized for experiments excluded) of 
R26lef1 and R26lef1 CD19wt/cre mice. 
 
During the monitoring period 18.5% of the control and 34.5% R26lef1 CD19wt/cre mice died 
of disease (Table 23). While skin and infectious diseases were almost equally distributed, 
there appeared to be a bias in neoplastic events for the R26lef1 CD19wt/cre population. Here, 
six times more animals showed neoplasia when compared with the control population. 
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These solid tumors occurred mostly in the liver (4 cases), followed by the gut (2 cases) 
and one was localized in muscle tissue. Three of these tumors were tested for lymphocyte 
infiltration via FACS analysis, which neither showed. Also the deaths with unknown 
reasons showed a bias towards R26lef1 CD19wt/cre mice. The majority of these mice most 
likely died due to infectious diseases or undetected neoplastic events. During the whole 
monitoring period only one leukemic event occurred. Mouse 550 (R26lef1) developed T 
cell leukemia with onset after 14 months (see Table 23). Nevertheless both populations 
showed comparable survival (see Figure 18). 
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Figure 18 Kaplan-Meyer curve of R26lef1 and R26lef1 CD19wt/cre mice. For this Kaplan-Meyer curve only mice 
which died from diseases were defined as event of death. R26lef1 CD19wt/cre (n = 58), R26lef1 (n = 65) 
 
The Kaplan-Meyer curve however shows no significant difference in survival between both 
populations. Until day 400 the course of both survival curves is nearly identical. In the 
remaining period only small differences are visible, with a possible better survival of 
control mice, which is however not significant. 
 
 
 
66 
 
5.2.1 No differences in cell morphology  
At random time points bone marrow and peripheral blood smears of exemplary mice were 
stained and analyzed by trained personnel for phenotypic abnormalities (see Figure 19). 
 
Figure 19 Exemplary peripheral blood and bone marrow smears. Peripheral blood and bone marrow smears 
were stained with Pappenheim protocol. The figure shows one example from bone marrow and from the 
peripheral blood from R26lef (control, left) and R26lef1 CD19wt/cre (right). 
 
Significant differences in lymphocyte morphology or quantity were neither observed in the 
bone marrow nor in the peripheral blood samples of control and R26lef1 CD19wt/cre mice. 
Some mice exhibited signs of infection, like activated B cells in the peripheral blood, but 
these observations were not genotype dependent.  
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5.2.2 R26lef1 CD19wt/cre mice show normal leucocyte counts 
The complete blood counts were prepared for R26lef1 CD19wt/cre and R26lef mice every 
eight weeks to detect possible disturbances in the blood composition. The results for male 
and female mice are depicted separately in Figure 20.  
Figure 20 Number of leucocytes in the peripheral blood. Peripheral blood from the tail vein of R26lef and R26lef1 
CD19wt/cre mice was analyzed at an interval of eight weeks by complete blood counts. The graph depicts the 
mean leucocyte count of the different strains in female (left) and male mice (right). Data points represent at 
least 10 animals each (n≥10). Error bars represent SEM (Standard error of means).   
 
Both genotypes showed little difference in their leucocyte counts. While the leucocyte 
count in female mice had a downward trend over the term of 64 weeks it remained stable 
in their male counterparts. The white blood cell count (WBC) appeared to be independent 
from the genotype, as the course of R26lef1 and R26lef CD19wt/cre was very similar over the 
term of 64 weeks in both sexes. The only discrepancy can be seen for eight week old 
females, where R26lef1 mice apparently have a decreased number of leucocytes. This 
difference however levels out until week 16, after which the females of both strains have 
virtually the same WBC again (see Figure 20). Neither in male nor female mice were any 
significant differences observed. A small number of animals were monitored for up to 80 
weeks, but also exhibited no significant differences in the WBC between both genotypes 
(data not shown). 
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5.2.3 Decreased percentage of B cells in the PB of R26lef1 CD19wt/cre mice 
While leucocyte counts did not reveal any changes in the blood composition between the 
two genotypes, the percentage of B cells in the lymphocyte population in the peripheral 
blood appears to be altered. The mean percentage of B cells in the peripheral blood of 
R26lef1 CD19wt/cre mice was at all-time points, except one, lower compared to R26lef1 mice. 
This trend was more pronounced in male mice where the percentage of B cells was 
significantly reduced at 32, 48 and 72 weeks (see Figure 21). In female mice the difference 
was only significant at 72 weeks.  
 
Figure 21 Percentage of B cells in the lymphocyte fraction of the peripheral blood of males and females. Every 
8 weeks blood was collected from the tail vein of R26lef1 CD19wt/cre and their R26lef1 littermates. Cells were 
stained for lymphocytes (CD45 subpopulation), B cells (Lymphocytes & B220) and T cells (Lymphocytes & 
CD5). The figure shows the mean percentage of B cells in the lymphocyte population, each data point 
represents 3-24 individuals. Error bars represent SEM. *p≤0.05, **p≤0.01, ***p≤0.001 calculated by independent 
two-sided student’s t-test. 
 
Since the percentage of B cells in the lymphocyte population from the peripheral blood is 
not significantly different between male and female mice (data not shown) the following 
figure shows the results for the combined results for both sexes each of each strain.  
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Figure 22 Percentage of B cells in the lymphocyte fraction of the peripheral blood combined sexes. Every 8 
weeks blood was collected from the tail vein of R26lef1 CD19wt/cre and their R26lef1 littermates. Cells were stained 
for lymphocytes (CD45 subpopulation), B cells (Lymphocytes & B220) and T cells (Lymphocytes & CD5). The 
figure shows the mean percentage of B cells in the lymphocyte population. Error bars represent SEM. *p≤0.05, 
**p≤0.01, ***p≤0.001 calculated by independent two-sided student’s t-test. Each data point represents 13-52 
individuals.  
 
Figure 22 shows a highly significant trend towards a reduced number of B cells in the 
lymphocyte fraction of the peripheral blood in R26lef1 CD19wt/cre mice. The reduction is 
significant at 16 (nlef1=14 vs. nlef1 CD19cre=52), 32 (nlef1=44 vs. nlef1 CD19cre=17), 48 (nlef1=35 
vs. nlef1 CD19cre=18), 64 (nlef1=37 vs. nlef1 CD19cre=25) and 72 (nlef1=18 vs. nlef1 CD19cre=16) 
weeks of age. The mean reduction over the whole monitoring period is 6.73% (95% 
confidence limits: 3.23-10.22%). 
 
5.2.4 The percentage of B cells is reduced in the spleen and in the BM 
Additionally to the percentage of B220 positive cells in the lymphocyte fraction of the 
peripheral blood the B cell content of the spleen and the bone marrow was determined by 
FACS based analysis. The percentage of B cells in the bone marrow and in the spleen 
was significantly different between age and sex matched R26lef1 and R26lef1 CD19wt/cre 
mice (see Figure 23). 
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Figure 23 Percentage of B cells in spleen and bone marrow. Cells from the spleen and the bone marrow of age 
and sex matched R26lef1 and R26lef1 CD19wt/cre mice were analyzed via FACS for their percentage of B cells (B220 
positive). For the bone marrow percentage of B220 cells is given compared to all CD45 positive cells. In the 
spleen the percentage of B220 positive cells in the CD45 positive lymphocyte population was analyzed. The 
scatter plot shows mean and standard error of mean (whiskers). The included samples are age and sex matched 
individuals (Bone marrow n=15, Spleen n=19), statistical analysis was performed via two-tailed student’s t test. 
Error bars represent SEM. 
 
The percentage of B cells was reduced in the bone marrow by 2.2% and about 5% in the 
spleen (see Figure 23). The differences were significant in both organs. To test whether 
these changes were due to induction of apoptosis the percentage of Annexin V negative 
B cells was measured in the bone marrow.   
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Figure 24 Annexin V negative B cells from the bone marrow. Bone marrow samples were collected from freshly 
sacrificed R26lef1 and R26lef1 CD19wt/cre mice (each five age and sex matched individuals (n=5)). The samples 
were stained with CD45, B220 and Annexin V and subsequently analyzed via FACS. The Figure shows mean 
percentage of Annexin V negative B220 positive cells. Error bars represent SEM 
 
Figure 24 shows the percentage of B cells without the apoptotic marker Annexin V. No 
significant difference was detected, but B cells from R26lef CD19wt/cre mice showed less 
often Annexin V positive B cells (average Annexin V negative B cells: 58.32% (control) 
vs. 64.20% (R26lef1 CD19wt/cre); n =5). 
 
5.2.5 WNT signaling inhibits the proliferation of B cells from the spleen 
The R26lef1 CD19wt/cre mice showed a significantly reduced percentage of B cells in the 
bone marrow, the peripheral blood and in the spleen. It was tested whether this difference 
might be due to an inhibition of proliferation. Lymphocytes were isolated and proliferation 
was induced by stimulation with LPS, additionally the influence of different WNT proteins 
and LiCl were tested. Figure 25 shows the induction of proliferation of the B cells by 
genotype after 48 h (R26lef with or without CD19wt/cre). The graph clearly shows a 
proliferation of cells which were stimulated with LPS alone (uncolored bars) with a slightly 
higher induction in R26lef CD19wt/cre mice. The addition of WNT3a, WNT5b and WNT11 
had no visible impact on proliferation of LPS stimulated cells. WNT10b and LiCl however 
reduced significantly the proliferation of the B cells both tested genotypes in a similar 
range. The addition of LiCl nearly abrogated the proliferation.  
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The induction of proliferation in samples not stimulated with LPS remained low. WNT10b 
appeared to induce proliferation, but this might be an artifact since the addition also 
reduced survival (see Figure 26).  
 
 
 
Figure 25 Influence of WNT modulation on proliferation of B cells from the spleen. Lymphocytes from the 
spleens of R26lef1 or R26lef1 CD19wt/cre were isolated via Ficoll gradient centrifugation and stained with 5 µM/ml 
CellTrace Violet™ (Invitrogen) for 5 minutes. Afterwards the cells were washed 3x with RPMI + 10% FCS and 
seeded out at 2x106/ml. The WNT modulators WNT3a (0.4 µg/ml), WNT5b (1 µg/ml), WNT10b (1 µg/ml), WNT11 
(1 µg/ml) and LiCl (50 mM) were added alone or with 10 µg/ml LPS. Analysis was performed after 48 h of 
incubation via flow cytometry via MFI of B220 positive cells. All results were normalized to untreated control 
(100%). Figure shows average of four control (R26lef1 n=6) and six (R26lef1 CD19wt/cre n=6) experiments, except 
for LiCl (n=3). Error bars represent SEM.    
 
The survival of the B cells appeared to be unaffected by stimulation with WNT3a, WNT11 
and LiCl in samples without LPS, while WNT5b and WNT10b apparently reduced it. The 
reduction of cell survival might in part explain the data of Figure 25, since the used cell 
dye (CellTrace violet ®, Invitrogen) appears to have bleached in dead cells. The mean 
survival after 48 h without LPS stimulation was 26.5% in control and 35.18% in B cells 
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with Cre induced LEF1 expression. In samples treated with LPS alone the survival 
increased to an average of 50.1% for cells from control and 52.2% in cell from R26lef1 
CD19wt/cre mice. Due to the high variances between experiments none of these differences 
was significant.  
The stimulation with LPS generally increased the percentage of Annexin V negative (non-
apoptotic) B cells in all samples but the LiCl stimulated. Mice carrying the CD19wt/cre gene 
however seemed to survive less, but this effect was not significant (see Figure 26).  
 
 
Figure 26 Influence of WNT modulation on survival of B cells from the spleen. Lymphocytes from the spleens 
of R26lef1 or R26lef1 CD19wt/cre were isolated via Ficoll gradient centrifugation and stained with 5 µM/ml CellTrace 
Violet™ (Invitrogen) for 5 minutes. Afterwards the cells were washed 3x with RPMI + 10% FCS and seeded out 
at 2x106/ml. The WNT modulators WNT3a (0.4 µg/ml), WNT5b (1 µg/ml), WNT10b (1 µg/ml), WNT11 (1 µg/ml) and 
LiCl (50 mM) were added alone or with 10 µg/ml LPS. Analysis was performed after 48 h of incubation via flow 
cytometry with an Annexin V and B220 staining. All results were normalized to untreated control (100%). Figure 
shows average of four control (R26lef1 n=4)) and six (R26lef1 CD19wt/cre n=6) experiments, except for LiCl (n=3). 
Error bars represent SEM.       
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Also the influence of different WNT modulators on B220 positive cells in the bone marrow 
was tested. The results of Figure 27 show an increased proliferation response to LPS 
stimulation. 
 
Figure 27 Influence of WNT modulation on proliferation of B cells from the bone marrow. Lymphocytes from 
the spleens of R26lef1 or R26lef1 CD19wt/cre were isolated via Ficoll gradient centrifugation and stained with 5 
µM/ml CellTrace Violet™ (Invitrogen) for 5 minutes. Afterwards the cells were washed 3x with RPMI + 10% FCS 
and seeded out at 2x106/ml. The WNT modulators WNT3a (0.4 µg/ml), WNT5b (1 µg/ml), WNT10b (1 µg/ml), 
WNT11 (1 µg/ml) and LiCl (50 mM) were added alone or with 10 µg/ml LPS. Analysis was performed after 48 h 
of incubation via flow cytometry via MFI of B220 positive cells. All results were normalized to untreated control 
(=100%). Figure shows average of three control (R26lef1 n=3) and three (R26lef1 CD19wt/cre n=3) age and sex 
matched individuals. Error bars represent SEM. 
 
Whereas few unstimulated cells proliferated, the LPS treated B220 positive cells of R26lef1 
CD19wt/cre mice showed a distinct proliferative response. It was higher in all LPS treated 
samples compared with the control animals, but differed only slightly between when 
additionally treated with WNT modulators. No significant difference between the 
genotypes was detected.  
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5.2.6 No significant impact of LiCl treatment in vivo 
In order to test the influence of active WNT signaling on the B cell population in vivo, three 
age and sex matched individuals from both genotypes were subjected to LiCl treatment 
to inhibit GSK3 and subsequently to activate the WNT signaling pathway. The treatment 
of mice with 300 mg/ml LiCl in the drinking water induced no significant changes in the 
percentage of B cells (see Figure 28). The normalized results show a slight reduction of 
the percentage of B cells in R26lef1 CD19wt/cre mice, but this was not significant. This effect 
might be due to a nearly complete lymphopenia (≈7% lymphocytes in WBC) in one 
individual of this group. The mouse died after weeks 5 of treatment for unknown reasons.  
 
 
Figure 28 In vivo LiCl treatment. Ten month old R26lef1 (n=3) and R26lef CD19wt/cre (n=3) mice were treated with 
300 mg/L LiCl in the drinking water ad. libitum for four weeks. Four weeks before treatment and after two and 
four weeks after treatment begin peripheral blood was collected from the tail vein and analyzed via flow 
cytometry (left) and complete blood count (right). Cells were stained for lymphocytes (CD45 subpopulation), B 
cells (Lymphocytes & B220) and T cells (Lymphocytes & CD5). The figures show the mean percentage of B 
cells or leucocyte count for each genotype normalized to pretreatment situation. Error bars represent SEM.   
 
The WBC of the LiCl treated mice in both groups exceeded after two weeks the 
pretreatment situation. Since the B cell fraction remains stable, this increase is likely due 
to expansion of non B cells. After 4 weeks the mean WBC dropped under the pretreatment 
level (see Figure 28). This effect appeared to be genotype independent. In one mouse 
(Mouse 660, R26lef1 CD19wt/cre) the lymphocyte population decreased rapidly in the four 
weeks of treatment. The mouse became weak, immobile and dehydrated and was 
sacrificed for ethical reasons after the fourth week of treatment.   
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5.3 The R26lef1 CMV-cre strain 
The first R26lef1 CMV-cre mice were born in September 2012. With a total population 
number of 19 animals (13th June 2013) the colony is relatively small, therefore all results 
show the combined results of both sexes. The experiments concerning this strain are not 
concluded and will go on for at least another six months.   
In contrast to R26lef1 CD19wt/cre mice some mice with CMV dependent Cre expression 
showed physiological abnormalities, which are shown in a later paragraph. The R26lef1 
CMV-cre strain was healthy, and fertile and showed no obvious genotype dependent 
behavioral abnormalities. For all following experiments only littermates served as control 
to avoid time dependent alterations.  
Since the CMV promoter allows a nearly ubiquitous expression of the Cre recombinase, 
the LEF1 transgene expression was also to be expected in nearly all tissues. In contrast 
to the CD19 promoter controlled Cre expression the GFP expression is not limited to the 
B cell compartment. Figure 29 shows exemplary the expression also in T cells and in other 
not further defined leucocytes. 
 
Figure 29 Exemplary GFP expression in leucocytes from the peripheral blood. Flow cytometric analysis of 
peripheral blood from mouse #729 (R26lef1 CMV-cre, age 16 weeks). The blood was collected from the tail vein 
and stained for CD5 (T cells), CD45 (leucocytes) and B220 (B cells). The left Panel depicts GFP expression in 
CD45 positive cells. The dot plot on the right shows the distribution of B and T cells of the GFP and CD45 
positive cells. 
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On average 55.9% of all leucocytes were tested positive for the reporter (n = 16; 8 weeks) 
(data not shown). The GFP expression is quite variable in the different subpopulations 
(see Figure 30).  
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Figure 30 Percentage of GFP positive cells in peripheral blood subpopulations. Peripheral blood from R26lef1 
CMV-cre mice (8 weeks old, n = 14) was analyzed via flow cytometry. Cells were stained for leucocytes (CD45), 
B cells (CD45, B220) and T cells (CD45, CD5). The plot shows the mean percentage of GFP positive cells in each 
subpopulation. Error bars represent SEM.   
 
The Cre induced recombination and subsequent expression of GFP was reasonably 
effective for white blood cells in the R26lef1 CMV-cre strain, however there were 
differences between different subpopulations (see Figure 30). The ration of the mean GFP 
positive cells was 58.5% for leucocytes, 69.8% for B cells and 45.5% for T cells (n = 16; 
8 weeks). Therefore the recombination efficiency was lower in B cells for this strain when 
compared to R26lef CD19wt/cre mice (69.8% vs 76.0%).  
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5.3.1 Trend towards reduced percentage of B cells in the peripheral blood 
Independent of the transgene expression the leucocyte count was not significantly 
affected in the peripheral blood of R26lef1 CMV-cre mice when compared to control 
littermates (see Figure 31).  
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Figure 31 Number of leucocytes in the peripheral blood. Blood from the tail vein of R26lef1 and R26lef1 CMV-cre 
mice was collected every 8 weeks and analyzed with COULTER® Ac·T diff2™. The results show mean leucocyte 
counts for each strain. Each data points represents 3-29 individuals. Error bars represent SEM.   
 
Similar to the R26lef1 CD19wt/cre strain the R26lef1 CMV-cre showed a trend towards 
reduced percentage of B cells in the lymphocyte population of the peripheral blood.    
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Figure 32 Percentage of B cells in the peripheral blood of R26lef1 CMV-cre and control mice. Every 8 weeks 
blood was collected from the tail vein of R26lef1 CMV-cre and their R26lef1 littermates. Cells were stained for 
lymphocytes (CD45 subpopulation), B cells (Lymphocytes & B220) and T cells (Lymphocytes & CD5). The figure 
shows the mean percentage of B cells in the lymphocyte population. Each data points represents 3-29 
individuals. Error bars represent SEM.  
 
As Figure 32 shows the average percentage of B cells in the lymphocyte fractions of 
R26lef1 CMV-cre was lower all time points (8 weeks: 43.8 vs 41.9; 16 weeks: 49.6 vs 41.0; 
24 weeks: 49.0 vs 39.5; 32 weeks 51.2 vs 49.6). The mean for all time points was therefore 
reduced by 5.4% (48.4% (R26lef1) vs. 43.0% (R26lef1 CMV-cre)).  
 
5.3.2 Skull deformations 
Besides the probable influence on the B cells the R26lef CMV-cre strain also showed skull 
deformations. Up to this point, only three R26lef1 CMV-cre mice were dissected. The 
animals had an overall shortened skull length, which gave the animals a more compact 
head appearance (see Figure 33). 
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Figure 33 Skull deformation of R26lef1 CMV-cre mice. The upper panel shows a 20 week old male control mouse 
on the left and an R26lef1 CMV-cre littermate on right side. The lower panel shows the corresponding skulls 
dorsal view. The nasal bone of the control skull was not preserved, but is present in the R26lef1 CMV-cre skull. 
 
Especially the frontal and the premaxilla bones were shorter when compared to the control 
skull. The shortening of the skull was not uniform and can be barely noticeable in some, 
but was quite obvious in most cases. Apart from the skull deformations no other 
abnormalities in teeth, organs or bones were detected.  
 
5.4 Phenotype R26lef1 Cr2-cre 
The R26lef Cr2-cre was the second strain with Cre induced LEF1 expression in their B 
cells, which was tested in this project. It was however generally neglected in favor for the 
CD19 dependent model. Therefore only six mice of this strain were born and the 
monitoring is incomplete. Due to the low number both sexes will be combined for the 
following results.     
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5.4.1 General description 
The R26lef1 Cr2-cre strain is healthy and fertile. The GFP expression is restricted to B cells 
with an average recombination efficiency of 85% (n=6) (see Figure 34).  
 
Figure 34 GFP expression in R26lef1 Cr2-cre mice is restricted to B220 positive B cells. Exemplary flow 
cytometric analysis of peripheral blood of an R26lef1 Cr2-cre mouse. Blood cells were stained for CD45, CD5 & 
B220. The figure shows the GFP versus the B220 signal in the lymphocyte fraction of the peripheral blood.  
 
The peripheral blood was only monitored from week 40 to 72 in five animals (see Figure 
35 & Figure 36). Cr2 dependent LEF1 expression had no significant impact on leucocyte 
number in the peripheral blood. 
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Figure 35 Number of leucocytes in the peripheral blood of R26lef1 Cr2-cre mice. Blood from the tail vein of six 
R26lef1 Cr2-cre mice (n=6) and their R26lef1 (n=6) littermates (sex matched) was collected at the indicated time 
points and analyzed with COULTER® Ac·T diff2™. The results show mean leucocyte counts for each strain, 
error bars represent SEM.   
 
The percentage of B cells in the lymphocyte fraction of the peripheral runs parallel to the 
R26lef1 control mice (see Figure 36). Overall no significant differences to the control mice 
were observed.  
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Figure 36 Percentage of B cells in the peripheral blood of R26lef1 Cr2-cre and control mice. From week 40 to 
week 72 blood was collected from the tail vein of six R26lef1 Cr2-cre (n=6) and their R26lef1 (n=6) littermates. 
Cells were stained for lymphocytes (CD45 subpopulation), B cells (Lymphocytes & B220) and T cells 
(Lymphocytes & CD5). The figure shows the mean percentage of B cells in the lymphocyte population. Error 
bars represent SEM. 
  
83 
 
5.5 Influencing the WNT signaling in CLL cells 
As a model for constitutive WNT signaling and high levels of LEF1 in B cells chronic 
lymphocytic leukemia (CLL) cells were chosen. These cells were used to test the effect of 
WNT modulation in these cells.  
 
5.5.1 WNT library in CLL  
In the first experiments the influence of different 75 different substances on viability of CLL 
cells and PBMCs and B cells from healthy donors were tested.  
 
Figure 37 Viability of CLL cells treated with WNT activators. The three individual heatmaps show the relative 
impact of 26 different WNT activators in concentrations from 100 nM to 100 µM on cell viability of CLL cells as 
well as PBMCs and B cells of healthy donors. Cell viability is shown relative to vehicle control and was 
measured after 24 h of incubation. nCLL= 5; nPBMC= 5; nB cells = 3. Green indicates high viability, red low cell 
viability measured by ATP-assay. Experiments were carried out in cooperation with Lukas Peiffer. CLL = 
chronic lymphocytic leukemia; B = B cells (healthy donor); PBMC = peripheral blood mononuclear cell (healthy 
donor) 
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Of the WNT activators most reduced the cell viability in CLL cells at high concentrations, 
with the exception of QS-11 (see Figure 37). The other traditional WNT Activators, which 
work via inhibition of GSK3β, were rather toxic for CLL cells at the tested concentrations. 
B cells from healthy patients were far less affected by the tested compounds in 
comparison. No WNT activator increased the viability of PBMCs or B cells from healthy 
patients. 
 
Figure 38 Viability of CLL cells treated with WNT inhibitors. The three individual heatmaps show the relative 
impact of 50 different WNT inhibitors in concentrations from 100 nM to 100 µM on cell viability of CLL cells as 
well as PBMCs and B cells of healthy donors. Cell viability is shown relative to vehicle control and was 
measured after 24 h of incubation. nCLL= 5; nPBMC= 5; nB cells= 3. Green indicates high viability, red low cell 
viability measured by ATP-assay. Experiments were carried out in cooperation with Lukas Peiffer. CLL = 
chronic lymphocytic leukemia; B = B cells (healthy donor); PBMC = peripheral blood mononuclear cell (healthy 
donor) 
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In the panel of WNT inhibitors none of the tested substances appeared to increase cell 
survival of CLL, B cells or PBMCs (see Figure 38). Five compounds (TNP-470, NO-ASA, 
JS-K, Trichostatin A & Doxorubicin) were specifically toxic for CLL cells. Of special interest 
for this work is the NO-ASA, which supposedly inhibits the β-catenin/TCF4 interaction and 
thereby inhibits canonical WNT signaling. 
 
5.5.2 NO-ASA as WNT inhibitors in CLL cells 
Several studies show an inhibition of canonical WNT signaling by NO-ASAs. Therefore 
the influence of two different NO-ASA derivatives, pNO-ASA (para-NO-ASA) and mNO-
ASA (meta-NO-ASA), were tested on mRNA expression levels. In the tested 
concentration only treatment with 100 µM for 24 h with pNO-ASA had a significant impact 
on the expression profile. Figure 39 shows a heatmap of up- and down-regulated genes 
that were sorted by their annotation with the Database for Annotation, Visualization and 
Integrated Discovery (DAVID)*.  
                                            
* http://david.abcc.ncifcrf.gov/home.jsp 
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Figure 39 Heatmap of array based genome wide mRNA expression analysis. Isolated CLL cells from four 
patients (n=4) were treated with DMSO (vehicle control), m- or pNO-ASA (100 µM) for 3 h. The total mRNA was 
isolated and submitted to analysis with Illumina human WG-6 v3 Expression BeadChips. Results were 
normalized (default settings) and analyzed with dCHIP software using following criteria: Fold change ≥ 2, 
difference of means ≥ 100, p ≤ 0.05. Significant regulated genes were submitted to the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) and classified for gene function and clustered by gene 
annotation. The up-regulated genes were grouped by the gene classification tool (medium stringency, 
enrichment score ≥ 2) and sorted by their difference of means. The down-regulated genes showed no obvious 
similarities in gene function and functional annotations, therefore the table lists the 20 genes sorted by the 
highest changes in the difference of mean signal. Heatmap shows normalized expression. Red indicates high 
signal, green low signal. HSP = heat shock protein 
 
The genes upregulated by pNO-ASA treatment can be assigned to three groups. The first 
group consists of genes that encode several heat-shock-protein interactors, especially 
chaperones from the DnaJ family (see Figure 39). In the second group of stress response 
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genes the heat-shock-proteins (HSP) dominate. The last group contains genes, mostly 
from the GADD45 family, which are expressed in response to DNA-damage. For genes 
downregulated by pNO-ASA treatment no obvious annotation pattern was found. These 
expression patterns, especially of the upregulated genes, rather hinted to an involvement 
of the NFκB and/or DNA-damage pathway than the WNT signaling pathway. Due to the 
high efficacy and selectivity of the NO-ASAs the project was nevertheless continued as a 
potential drug for CLL treatment and new NO-ASA derivatives were developed. From a 
total of 22 derivatives pNO-ASA, NOBA and NO-Naphtyl proved to be the most selective 
and effective derivatives to induce apoptosis in primary CLL cells in vitro (personal 
communication with Sylvia Krallmann & Alexandros Liakos, see  
Supp. Table 1).    
 
5.5.3 New derivatives 
The new derivatives were developed on the basis of pNO-ASA. They all share, as 
common features, a nitric oxide connected via a benzylic linker to different moieties (pNO-
ASA = acetylsalicylic acid; NOBA = benzoic acid; NO-Naphthyl = naphtoate). All 
compounds were synthesized by the organic chemistry in the workgroup of Prof. Dr. 
Albrecht Berkessel.  
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Figure 40 Chemical structures of pNO-ASA, NOBA and NO-Naphtyl. pNO-ASA: 4-[(nitrooxy)methyl]phenyl 2-
(acetyloxy)benzoate; NOBA:  4-[(nitrooxy)methyl]phenyl benzoate, No-Naphtyl: 4-[(nitrooxy)methyl]phenyl 
naphthalene-1-carboxylate 
 
Early experiments showed that the active subunit of NO-ASA is very likely the benzyl 
linker, which is supposed to form a chinone methide upon metabolization. The substances 
NOBA and NO-Napthyl were developed for their ability to allow effective generation of the 
chinone methide to increase their efficacy (see Figure 40). After successful in vitro 
experiments performed by Sylvia Krallmann and Alexandros Liakos the substances were 
put forward for in vivo tests (see  
Supp. Table 1). The following Figure 41 shows the inhibition of tumor growth by NOBA 
and NO-Naphtyl treatment which were administered in an equivalent dose to mice 
engrafted with cells from the B cell line JVM3.    
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Figure 41 JVM3 xenograft model. Immunodeficient SCID beige mice were injected subcutaneously with 1x107 
JVM3 into the right flank. When palpable solid tumors were detectable the mice were treated every other day 
with 8 mg/kg NOBA, 9.47 mg/kg NO-Naphtyl or sesame oil alone (vehicle control) by peritoneal injection. The 
tumor diameter was measured using a caliper, tumor volume was approximated with the formula volume ≈ 
(Length*(0.5*Width2)). A: The graph shows the mean tumor volumes of each treatment group for 19 days under 
treatment. The error bars represent SEM. B: The table shows the calculated p values and the inhibition ratio 
(IR) for each day between control and NOBA group. p was calculated with student’s independent two-sided t-
test, p ≤ 0.05 are depicted in bold. IR was calculated with the following formula IR = (l - Vtest/Vcontrol) x 100 (%). 
 
The tumor growth in control and in NO-Naphtyl mice was rapid with a mean tumor volume 
of 891 mm3 and 731 mm3 respectively at day 19. The difference in mean tumor volume 
between the two groups appeared to be due to smaller tumors at the start of the treatment 
in the NO-Naphtyl group. Overall the mean tumor volume of NO-Naphtyl treated mice rose 
parallel to the control group, therefore the compound had no significant inhibitory effect 
on the tumor growth in this model. In contrast the treatment with NOBA resulted in a split 
of the mean tumor volume curves of the NOBA and control group after day 9. Starting 
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from this day the difference in tumor volume between these groups was highly significant 
(Figure 41B). The inhibition ratio reaches its maximum on day 17 with an IR of 65.33%.     
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6 Discussion 
The WNT signaling pathway plays a pivotal role in many different biological mechanisms 
like embryogenesis, cell fate, proliferation, cell migration. It appears to have developed 
quite early in evolution and has evolved into a highly complex and tightly regulated 
signaling network. The knowledge about this pathway and its functions has expanded 
rapidly over the last two decades, especially in regard of stem cell biology. The WNT 
signaling is known to control stem cell differentiation, self-renewal and proliferation. In 
addition, its influence on hematopoiesis and hematologic malignancies is currently under 
investigation. An important role for the integration information through WNT signaling have 
the down-stream transcriptionfactors, but their role in hematopoiesis and hematologic 
malignancies is poorly understood. Therefore, this project was designed to elucidate the 
role of the transcriptionfactor LEF1 in the B cell development and its possible role as 
driving factor for B cell leukemia in vivo. In addition to this role, the influence on other 
tissues was analyzed in a newly developed mouse model.  
 
6.1 The role of WNT signaling in hematopoiesis 
The WNT signaling pathway plays an important function during hematopoiesis, especially 
for lymphocytes. Most information is hereby available for the early stages of their 
development, namely from HSC to pre B cells (see Figure 9). In this phase the activation 
of the WNT/β-catenin pathway appears to promote the self-renewal, while non-canonical 
WNT signaling induces proliferation and differentiation (Malhotra and Kincade, 2009). 
Predominantly the evidence for this effect comes from in vitro experiments in which HSCs 
or common lymphoid progenitor (CLP) cells are stimulated with recombinant proteins like 
WNT3a, which usually leads to WNT/β-catenin signaling, or WNT5a, which predominantly 
activates non-canonical WNT signaling (Van Den Berg et al., 1998; Malhotra et al., 2008). 
But these findings are not easily reproduced in mice. Some findings are still in line with 
the in vitro experiments, for example that WNT3a deficient HSCs in wild type mice are 
defective in their self-renewal, but others are not (Luis et al., 2009). Heterozygous WNT5a 
knock-out leads to increased proliferation of myeloid and lymphoid cells in mice and to 
corresponding leukemia and lymphomas (Liang et al., 2003). This result appears to be 
opposing to the knowledge about WNT stimulation of HSCs in vitro, where WNT5a 
induces proliferation (Malhotra et al., 2008). Reasons for this contradiction might be 
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changes in the output of canonical and non-canonical WNT signaling in different cell types, 
differentiation stages or in the microenvironment. The changes in the output can be 
achieved for example by expression of different co-receptors, modulators or cross-talk 
with other pathways.  
 
6.2 The LEF1 mouse models 
Up to date there are more than 20 different mouse models concerning the WNT pathway, 
ranging from knock-out out models of various pathway members to WNT reporters, which 
indicate pathway activity (Lustig et al., 2002). With the transcription factor LEF1 deal only 
four relevant models. The knockout model from van Genderen established 1994 and a 
mutation model published in 2000 deals with dysfunctional LEF1 (Galceran et al., 2000; 
van Genderen et al., 1994). The knock-out and the LEF1 mutation model revealed severe 
and terminal dysfunctions in organogenesis during the embryonic development. In a 
overexpression model driven by the K14 promoter, showed a role of LEF1 in the control 
of hair bud stem cells (Zhou et al., 1995). In the latest LEF1 model, the transcriptionfactor 
is transduced to HSCs, which then are transplanted to wild type mice pretreated with 
chemotherapeutics (Petropoulos et al., 2008). All these models are somewhat restricted 
in their use, since the complete knock-out or LEF1 mutation proved to a lethal phenotype 
early after birth or are not readily adaptable to other cell types, like the K14 or the LEF1 
transduction model. To close this gap the R26lef1 mouse model was developed. This 
model is based on a targeted transgene insertion into the ROSA26 locus. This locus is 
well known and often used since insertions do not seem to produce any phenotype 
(Friedrich and Soriano, 1991). The targeting Vector used, is designed to enable 
transcription of any transgene in a Cre dependent manner. If Cre is not present a STOP 
cassette represses transcription of the transgene. In the presence of the Cre recombinase 
the STOP cassette, which is flanked by loxP sites, is excised, which puts the transgene 
under direct control of the CAG promoter and the expression is started. In vivo this means 
a start of transgene expression in every cell with targeted insertion (R26x/x) and presence 
of Cre recombinase. Nowadays, there is a broad spectrum of mouse strains expressing 
Cre in various tissues, cell types or developmental stages are available, the expression 
can therefore be restricted to many different target cells or tissues. For this work the cDNA 
sequence of full length human LEF1 was cloned into an expression cassette and inserted 
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into the Rosa26 locus. This allows controlled and targeted expression of full length LEF1 
in various tissues or cells, as long as according Cre deleter strains are available. 
Therefore, it is an easily adaptable model to answer questions whenever transgenic 
expression of LEF1 expression is desired in vivo. To be of any use for future scientific 
work it is important to know, if the transgene expression is stable and if the expressed 
protein is functional.  
 
6.2.1 Proof of principle of the R26lef1 mouse model 
The insertion into the Rosa26 locus was tested by southern blot using radioactive probes 
targeting gfp and the neo resistance cassette, which both are also integral part of the 
targeting vector. The southern blot analysis of the embryonic stem cells prior to blastocyst 
injection were performed by co-workers of Dr. Thomas Wunderlich. Only stem cells with 
correct patterning in the southern blot analysis were put forward for blastocyst injection. 
Therefore correct insertion into the Rosa26 locus can be regarded as given.  
PCR analysis of gDNA samples of the founder mouse of the R26lef1 strain proved the 
presence of the neo, gfp and human lef1 gene in the genome of this strain, which indicates 
insertion of the targeting vector (data not show). The founder mouse was crossed 
immediately with the CD19wt/cre deleter strain to induce LEF1 expression in B cells (see 
Figure 12). Some members of the resulting generation therefore carried the new 
transgene and expressed Cre recombinase in their B cells. As expected this led to an 
expression of GFP, which is restricted to the B220 positive (B) cells (see Figure 12). The 
GFP signal was stable for more than 6 months, indicating a stable and constant transgene 
expression (see Figure 13). The depletion efficiency in the R26Ief1 CD19wt/cre strain, 
indicated by GFP expressing B cells in the peripheral blood, reached an average of about 
76%. This is about 20% lower than it was described by Demircik and coworkers for the 
CD19wt/cre strain in an similar experiment (Demircik et al., 2013). Still the large majority of 
the B220 positive cells expressed GFP, which is acceptable for most experiments. The 
other two used deleter strains also achieved good depletion ratios in the target cells of the 
peripheral blood. The CMV-Cre dependent strain had GFP expression in 69.8% of the 
B220 positive cells in the peripheral blood, while the Cr2-Cre achieved 85% in average 
(see Figure 29 & Figure 34). The high efficiency of the Cr2 driven Cre expression might 
be debatable since the sample number is small and the measurements took place after 
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40 weeks, but overall it is obvious that the STOP cassette R26lef1 transgene is efficiently 
deleted in B cells in vivo. The efficient depletion is not restricted to B cells as it is shown 
for R26lef CMV-Cre mice (see Figure 30), but has to be tested anew for each cell type and 
corresponding Cre deleter strain.  
Another important point is the resulting the LEF1 expression. While the CAG promoter is 
highly efficient at the ROSA26 locus in murine embryonic stem cells, the overall 
expression ratio of transgenic LEF1 appears to be moderate (Chen et al., 2011). The 
results from the immunoblot analysis of murine B cells from the spleen showed a distinct 
overexpression (see Figure 14), this is however unsurprising as wild type B cells virtually 
do not express the transcriptionfactor at this stage of their development (Reya et al., 
2000). Intracellular staining of LEF1 in B cells would have been a good alternative to 
immunoblotting, but subsequent analysis by FACS or fluorescence based microscopy 
were either unsuccessful or not reproducible. A comparison on mRNA level also seemed 
not advisable, since this information does not necessarily reflect the protein amount. Other 
aspects, like protein stability and other regulating mechanisms, can influence the overall 
outcome. Possibly the best information about the strength of the LEF1 expression 
provided by the transgene comes from R26lef1 CMV-cre MEFs (see Figure 15). Here the 
LEF1 was exclusively detectable in the nucleus, with background signal only in the rest of 
the cells. This hints a moderate expression in these cells with high metabolic activity, since 
high expression ratios would implement relevant quantities of the protein outside of the 
nucleus. At least newly translated protein, as well as LEF1 not yet imported into the 
nucleus, would be present in detectable amounts in the ER. Moreover, the fact that the 
reporter GFP is only detectable by FACS and not by immunofluorescence, in MEFs as 
well as in murine B cells, speaks for a rather low expression ratio. The functionality of the 
transgenic LEF1 was shown in MEFs, where a distinct difference between LEF1 positive 
and negative cells was detectable. MEFs without Cre recombinase activity, for example 
with R26lef1 background, have no detectable LEF1 expression (see Figure 17). Therefore, 
all LEF1 positive cells can be regarded as cells with successful depletion of the stop 
cassette. These cells also have far more often Axin2 in their nucleus. This suggests that 
the transgenic LEF1 induced WNT signaling, as nuclear Axin2 can be regarded as sign 
for the activity of the pathway and of an active negative feedback loop in these cells (see 
Figure 15) (Topol et al., 2009).  
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6.2.2 Effects of LEF1 expression 
For this study R26lef1 mice were crossed with three different Cre deleter strains. The 
CD19wt/cre strain which restricts the expression of the transgenic LEF1 to the B cells, 
starting with the earliest B cells, is the best analyzed. This strain shows a reduction of B 
cells, which was detectable in the bone marrow, the spleen as well as the peripheral blood 
(see Figure 22, Figure 23). This reduction was neither associated with changes of the 
lymphocyte phenotype, overall survival or sex (see Figure 18, Figure 19, Figure 21). 
Interestingly the difference in the percentage of B cells remained relatively stable between 
the bone marrow (3%), spleen (5%) and the peripheral blood (6%) (see Figure 22 & Figure 
23). This rather speaks for a stable B cell population, at least in the spleen and the 
peripheral blood and against an ongoing toxicity. Therefore, it seems like the effect of the 
LEF1 expression on the number of the B cells is restricted to the bone marrow and 
transitional B cells. In the bone marrow, the percentage of apoptotic B cells was measured 
in fresh samples and showed no difference between R26lef1 and control mice (see Figure 
24). This suggests that the upcoming reduction of B cells in the bone marrow is not due 
to increased apoptosis, which again speaks against transgene toxicity. Therefore the 
proliferation rate of B220 is most likely reduced in R26lef1 CD19wt/cre mice. It has to be 
noted that B220 not only detects B cells in the bone marrow, but also lymphoid progenitor 
cells, which still can differentiate into B, T and NK cells. However the expression of CD19 
and thereby of the Cre recombinase is usually thought to mark a high commitment to the 
B cell lineage. It is also the starting point of the LEF1 expression in this model, therefore 
only future B cells should be affected. In contrast to their progenitors HSCs and CLPs, 
active WNT/β-catenin signaling appears to be a mitogenic signal for pre-B cells (Reya et 
al., 2000). Therefore the meaning of active WNT/β-catenin seems to shift from induction 
of self-renewal in HSCs and CLPs towards a proliferative signal (Luis et al., 2009; 
Malhotra et al., 2008). It appears to be in direct opposition to the results of this study, since 
it might be deduced from the experiments with MEFs (see Figure 15), that additional LEF1 
increases the WNT/β-catenin dependent signaling, which therefore should increase the 
proliferation of the B cells. However, it cannot be excluded that the transgenic LEF1 
expression has the opposite effect in B cells, since all members if the TCF/LEF1 family 
can act as suppressors without transactivation by β-catenin or other factors. Therefore, it 
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is still to be determined if WNT/β-catenin activity is increased in B cells that express 
additional LEF1. Recommendation to answer this question will be discussed in a later 
paragraph (see paragraph 6.7).   
Interestingly, in later stages of developing B cells the stimulation of the WNT signaling 
pathway especially by WNT10b and LiCl inhibits the LPS induced proliferation of B cells 
from the spleen significantly (see Figure 25). LiCl strongly activates the WNT/β-catenin 
signaling pathway by inhibiting GSK3 Kinase activity. Since GSK3 is an integral part of 
several signaling pathways it cannot be excluded that the inhibition is due to off-target 
events. WNT10b is reported to stimulate the WNT/β-catenin signaling pathway in human 
hepatoma cell lines (Yoshikawa et al., 2007). Together with the strong reduction of B cell 
proliferation by LiCl it is a logical assumption that active WNT/β-catenin signaling reduces 
proliferation of LPS stimulated B cells from the spleen of R26lef1 CD19wt/cre mice in vitro. 
This appears to be true for both genotypes, which indicates that it is a general mechanism, 
which did not seem to be affected by expression of transgenic LEF1. Interestingly 
WNT10b seemed to stimulate growth also in the absence of LPS, but this was however 
more likely to be due to the reduction in cell survival of WNT10b treated B cells, which 
caused an artificial proliferation signal (see Figure 25 & Figure 26). Overall it has to be 
noted that no WNT stimulation whatsoever induced significantly different reactions 
between B cells from the spleen of R26lef1 CD19wt/cre and control mice. This implies that 
LEF1 function is either not needed for proliferation and survival or is compensated by 
other mechanisms at this developmental stage. The stimulation of B220 positive cells from 
the bone marrow, however, reveals an unexpected picture. Figure 27 shows a higher 
induction of proliferation in R26lef1 CD19wt/cre mice, which again is not significant, but can 
easily be identified as trend. This is in opposition with the overall result of reduced B cell 
numbers in the bone marrow, spleen and peripheral blood. LPS however also stimulates 
cells without B cell receptor which were present in the cell mix used for this experiments. 
The mitogen can, for example, induce proliferation of HSCs by TLR dependent signaling, 
which results in expansion of stem cells (Nagai et al., 2006). Therefore it is unclear, 
whether the expansion of B220 positive cells in R26lef1 CD19wt/cre by LPS stimulation was 
only due to proliferation of cells that are committed to the B cell lineage. Since the in vitro 
results of the proliferation assays do not readily explain the significant differences between 
the two genotypes, in vivo proliferation assay should by conducted in the future. In this 
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regard, it is unfortunate that the in vivo stimulation of the WNT signaling pathway by LiCl 
treatment of control and R26lef1 CD19wt/cre remained inconclusive (see Figure 28). Neither 
strain showed a significant difference in hematopoiesis, which might be due to inadequate 
LiCl dosage or monitoring period. The abortion of the experiments was caused by a death 
of an R26lef1 CD19wt/cre mouse, in which the lymphocyte population in the peripheral blood 
was depleted. If this was due to the treatment, to pathogens or to a combination of both 
remains unclear (see Figure 28 & Supp. Fig. 7). Also interesting in this regard, are the 
results from R26lef1 Cr2-cre mice. Despite the fact that the sample number and the 
monitoring period are too small for definite results Figure 36 shows a nearly identical 
percentage of B cells in the peripheral blood of test and control mice. The results from the 
CMV-cre induced strain in contrast show a not significant reduction (see Figure 32). Taken 
together the experiments with the R26lef1 mouse model support the results from Reya and 
colleagues, who postulated a restriction of LEF1 activity to B cells in the bone marrow 
(Reya et al., 2000). 
Next to the regulation of lymphopoiesis, LEF1 plays apparently also an important role in 
bone formation. Figure 33 shows typical skull deformations of an R26lef1 CMV-cre mice, 
which occur frequently in this strain. In contrast to the other two strains expressing 
transgenic LEF1, the transgene expression is started in this model during embryogenesis 
and is not restricted to a special tissue or cell type. This probably includes cells acting 
during bone formation, which in term express transgenic LEF1. Since LEF1 is already 
known to control osteoblast differentiation and proliferation it is not surprising that the bone 
formation is affected by the constitutive LEF1 expression (Kahler et al., 2006). The 
importance of the transcription factor in this process is further underlined by in vivo 
experiments with a mouse strain expressing mutated LEF1 with disrupted HMG domain 
(Galceran et al., 2004). This prohibited binding of LEF1 to the DNA and caused severe 
deformations of rib-cage bones. Interestingly the phenotype of the R26lef1 CMV-cre strain 
is highly similar to one observed in Axin2 null mice, in which the negative WNT regulator 
protein Axin2 is knocked-out (Yu et al., 2005). Axin2 null mice have a more compact skull, 
too. This is due to increased proliferation of osteoprogenitors and lead to fusion of cranial 
sutures at early postnatal stages (Yu et al., 2005). This very similar phenotype supports 
the theory that overexpression of LEF1 increases the WNT dependent signaling, since 
also the deletion of the negative WNT regulator Axin2 increases WNT/β-catenin signaling 
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in the Axin2 model. This activation in turn leads to the expansion of osteoblasts and 
premature fusion of the skull sutures, which can be observed in both models (Yu et al., 
2005).      
Concluding from all three LEF1 expressing strains it is clear that the influence on 
hematopoiesis is relatively small. This can be deduced from the complete blood counts, 
where no significant differences where observed (see Figure 20, Figure 31 & Figure 35). 
The differences in the blood counts are more likely due to pathogens. The health status 
of the animal facility was compromised several times by different pathogens during the 
monitoring period and the mice were treated, if possible, accordingly (see Supp. Fig. 7). 
Due to the long monitoring period and the mixing of genotypes in each cage, it can be 
more or less excluded that the significant differences are due to extrinsic factors. The 
same is true for the results of the B cell content of the bone marrow and the spleen (see 
Figure 23). However, the question remains if the relatively small impact of LEF1 on 
lymphopoiesis is due to the experimental setup or mechanisms of compensation, for 
example by Axin2 expression (see Figure 5 & Figure 16). The skull deformations, which 
highly resemble the phenotype observed in Axin2 null mice, hint that the expression of 
LEF1 most likely induces WNT/β-catenin dependent signaling. It remains unclear how 
strong this activation is, especially compared to the physiological WNT signaling (Yu et 
al., 2005).   
 
6.3 Comparison of LEF1 dependent mouse models 
Up today four major LEF1 dependent mouse models have been generated, the LEF1 
knock-out (KO) by van Genderen, the LEF1β-gal model by Galceran, the K14-LEF1 model 
by Zhou and the LEF1 transduced HSC model by Petropoulos (Galceran et al., 2000; van 
Genderen et al., 1994; Petropoulos et al., 2008; Zhou et al., 1995). In this chapter these 
models are compared to the R26lef1 strains to integrate the gained knowledge and to 
discuss advances and drawbacks of the new model. 
 
LEF1 knock out 
The LEF1KO was the first LEF1 dependent mouse model. It is based on a disruptive 
introduction of a neo resistance gene into the second exon of the HMG domain. This 
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abrogated any protein LEF1 expression, which resulted in an plethora of developmental 
defects in homozygous null mice (van Genderen et al., 1994). Especially the formation of 
teeth, hair, whiskers and the mammary glands were disturbed. Neither of these organs 
were affected in one of the new LEF1 expressing mouse strains. This is not unlikely as 
KOs of genes often create more severe phenotypes when compared to their 
overexpression models. Interestingly, no defects in the lymphoid compartment, especially 
in pre-B cells were detected in LEF1 null mice, which hints that the loss of LEF1 can be 
compensated. But is has to be noted that homozygous KO mice died in few weeks after 
birth. This prevents any long-term study of their hematopoietic system (van Genderen et 
al., 1994). Some observations appear to be quite the opposite from our R26lef1 CMV-cre 
model. While LEF1 KO mice developed a elongate and pointy snout, the snout of R26lef1 
CMV-cre is often shortened (van Genderen et al., 1994). If this reflects the opposite nature 
of the two model, or is a side-effect remains unknown.        
 
LEF1β-gal 
The LEF1β-gal model distinguishes itself from the knock-out model by the expression of 
a LEF1 β-galactosidase fusion protein. The β-galactosidase protein replaces the HMG 
domain of the LEF1, which results in a stable protein that can bind β-catenin but not to 
DNA (Galceran et al., 2000). This model showed severe disruption in brain development 
as well as in bone formation (Galceran et al., 2000, 2004). Especially the abnormalities in 
bone formation are partly due to the LEF1 dependent control of the dll1 gene, which is 
part of the Notch signaling cascade. This model is interesting since it only focuses on the 
transcriptional activity of LEF1 and to the fact that the integrated β-gal gene allows to 
detect cells and tissues with active LEF1 expression. Also noteworthy is the fact that the 
dll1 gene expression is controlled by LEF1 in vivo, a factor which blocks differentiation in 
B cells (Jaleco et al., 2001). Overall the phenotype is not as severe as known from the 
knock-out model. As recurrent feature the bone formation is affected, which is also the 
case in R26lef1 CMV-cre mice (Galceran et al., 2004).  
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K14-LEF1 
The K14-LEF1 model is the first model, which is based on LEF1 overexpression. In this 
model LEF1 is expressed under control of the K14 promoter. This resulted in atypical hair 
growth and tooth formation (Zhou et al., 1995). It was also the first model to prove the 
activity of human LEF1 in a murine system. Unfortunately, the observations from this 
model could not be reproduced in the R26lef1 CMV-cre model, in which also human LEF1 
should be overexpressed nearly ubiquitously, including cells with K14 promoter activity. 
The mice of the R26lef1 CMV-cre neither showed disoriented hairs or whiskers nor tooth 
deformation, which occur in the K14 model (Zhou et al., 1995). The differences are most 
likely due to inefficient cre recombinase activity in the corresponding cells, which failed to 
induce LEF1 expression in all cells, like it is shown for B and T cells (see Figure 29, Figure 
30). Another aspect is the activity of the CAG promotor, which might be inadequate in 
certain cell types. Additionally there might be strain specific differences as Zhou and 
colleagues used a not further defined mouse strain, which has a fair coat, whereas the 
R26lef1 mice have a C57BL/6 background (Zhou et al., 1995). 
 
LEF1 HSC  
The LEF1 transduced HSC model is the most similar model to the R26lef1 CD19wt/cre & 
Cr2-cre strains. In this model the LEF1 cDNA is transduced and expressed before any 
lineage decision during hematopoiesis. This actually can explain some of the differences 
to the LEF1 HSC model of Petropoulos et. al., where the target cells were transduced with 
a construct based on the MSCV (Murine Stem Cell Virus) LTR (Long Terminal Repeat), 
which allows for high expression ratios in murine stem cells and other cell types 
(Petropoulos et al., 2008). It is reasonable to expect that the MSCV based system leads 
to higher expression of transgenic LEF1, when compared to the R26lef1 based strains. 
This might, at least to some extent, explain the high leukemogenic potential in model of 
Petropoulos when compared to the newly developed model (compare Table 23, 
(Petropoulos et al., 2008). The publication of Petropoulos does not state which isoform or 
which species of LEF1 was transduced into the HSCs. This might be another reason for 
the difference between the two mouse models. The R26lef1 model uses human full-length 
cDNA without introns, therefore the β-catenin domain is present in the expressed protein. 
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It is likely that Petropoulos and colleagues used murine cDNA for their transduction 
experiments. Murine and human LEF1, however, share a very high identity (see Figure 1) 
and it was proven that murine β-catenin can interact with human LEF1 and is active in 
vivo (Hamada and Bienz, 2004; Zhou et al., 1995). In addition, the increased translocation 
of Axin2 in to the nucleus of LEF1 positive MEFs with R26lef1 CMV-cre background 
suggests that the human LEF1 functions as expected and increases WNT signaling (see 
Figure 16). Therefore it appears highly unlikely that the differences of the two models are 
due to inter-species issues. The transduction of HSCs however bears some risks in the 
regard of unspecific leukemia induction by uncontrolled virus integration. Petropoulos and 
co-workers neither tested for the number of integrations nor for the integrations sites 
(Petropoulos et al., 2008). Their study was also performed using only three control mice, 
which received an EGFP expressing transgene. Two of these mice were sacrificed rather 
early, therefore the mean monitoring period for the control mice was about 100 days less 
compared to the mice which received HSCs transduced with wild type LEF1. Overall the 
necessary work in LEF1 HSC model to transduce and transplant HSCs is quite high when 
compared to the simple mating of the R26lef1 based model. Also no targeted expression 
was implemented into LEF1 HSC model from Petropoulos and co-workers, which is 
probably responsible for the inconsistent type of leukemia that arise and decreases its 
uses as a murine disease model significantly (Petropoulos et al., 2008). Additionally, by 
the transduction of LEF1 and the necessary chemotherapy, the model bears the risk of 
unwanted off-target events, which are not foreseeable.  
 
6.4 Advantages and drawbacks of the R26lef1 mouse model 
The R26lef1 mouse model might prove as a powerful tool to analyze the function of LEF1 
in vivo. Compared by the clarity of the phenotype it seems to fall behind the other models. 
The LEF1KO and LEF1β-gal model produce strong defects in embryogenesis, which 
renders them unfit for analysis of postnatal LEF1 dependent regulation. The two knock-in 
models (LEF1 HSC & K14-LEF1) produce easily detectable phenotypes, too. This is 
probably due to the mediocre expression of LEF1 based on the CAG promoter in R26lef1 
mice. The CAG promoter is well suited for expression in stem cells, but appears to be 
inefficient in B cells. The assumption that the mild phenotype of the R26lef1 based model 
is due to the introduction of human LEF1 cDNA can be excluded since the K14-LEF1 
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model also uses human full length cDNA (Zhou et al., 1995). The necessary expression 
of the Cre recombinase and the GFP reporter gene might be regarded as a drawback of 
the new model, since both proteins are known to be toxic. The GFP expression in this 
model is only detectable by highly sensitive methods like flow cytometry and can therefore 
be regarded as very low. This renders any relevant toxicity unlikely. The Cre recombinase 
however can mediate toxicity by its ability to cleave DNA, which causes genetic instability 
(Silver and Livingston, 2001). The Cre-deleter strains used for this work are frequently 
used and no effect by Cre mediated toxicity was ever described. Additionally, the rather 
stable decrease in B cells from the bone marrow to the peripheral blood speaks against 
such a toxicity (see Figure 22 & Figure 23). Future experiments should nevertheless use, 
if possible, Cre deleter strains, with the ability for cre self-excision (Silver and Livingston, 
2001).   
Overall the R26lef1 models advantages are high adaptability, which will be further 
addressed in the outlook, and easy handling. The model also allows fast and easy 
production of high sample numbers, which even makes small effects detectable, like it is 
the case for the reduction of B cells in the R26lef1 CD19wt/cre strain (see Figure 21). The 
R26lef1 also has the potential to shed some light onto the role of the transcriptionfactor in 
the WNT signaling pathway in general and in several cancers and leukemia.  
 
R26lef1 in cancer models 
The LEF1 expression of R26lef1 mice showed no detectable oncogenic potential up today, 
independent of the used Cre-deleter strain. The observed increase in solid cancers in 
R26lef1 CD19wt/cre mice can be traced back to a decrease of surveillance by the immune 
system, since all available tumors were devoid of GFP expressing cells (see Table 23). A 
similar analysis would also be interesting for the R26lef1 CMV-cre, but this strain is not yet 
monitored for an adequate period of time. Nevertheless the R26lef1 based transgenic LEF1 
expression might offer some interesting options in different cancer models that are linked 
to the WNT signaling pathways, especially for leukemia models. One example is the Eµ-
TCL1 mouse model for CLL. In this model the leukemia is driven by the expression of an 
enhancer of the B cell receptor signaling. Surprisingly the induction of leukemia is 
postponed in Frizzled 6 deficient Eµ-TCL1 mice (Wu et al., 2009). This proves a link 
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between the WNT signaling and the leukemogenesis in this strain. A crossbreeding with 
the R26lef1 strain might have an opposite effect, which would implement strong ties 
between WNT signaling and the BCR signaling of leukemic cells, which is also suggested 
for the human disease (Lu et al., 2004a). Overall the number of possible combinations of 
different murine cancer models with R26lef1 strain is vast and cannot be discussed in detail, 
but additional promising options, with special regard to CLL, are presented in the outlook. 
 
6.5 WNT signaling in CLL 
One of the hallmarks of chronic lymphocytic, where the leukemic B cells usually have a 
mature phenotype, is the LEF1 expression (Erdfelder et al., 2010). The expression is 
already detectable during monoclonal B cell lymphocytosis (MBL), a state with many 
similarities to CLL like the monoclonal expansion of B cells, but without malignant 
proliferation. MBL, however, can advance to a CLL accompanied by rising LEF1 levels 
(Gutierrez et al., 2010b). This observation seems to fit the model first proposed by Lu and 
co-coworkers, which suggested that the WNT/β-catenin signaling pathway is constitutively 
activated and supports the survival of the leukemic B cells (Lu et al., 2004a). This led to 
the idea that the WNT signaling and its downstream transcriptionfactor LEF1 might not 
only be important for CLL cell survival, but also for the induction of the disease since LEF1 
apparently can drive leukemia induction (Petropoulos et al., 2008). In opposition to this 
hypothesis is the lack of leukemia cases in the R26lef1 mouse model. Neither the CD19wt/cre 
nor the CMV-cre induced LEF1 expression caused leukemia up to this date, which 
induction might even have been supported by cre induced genetic instability (see Table 
23). Furthermore, the LEF1 HSC model, while it shows leukemogenesis driven by LEF1, 
has a bias to myeloid leukemia and no case of a CLL like disease was reported 
(Petropoulos et al., 2008). All this data hint to the fact that LEF1 overexpression, while it 
appears to be highly important for CLL cells, probably needs other co-factors to induce a 
CLL like leukemia. There are most likely β-catenin independent processes at work, since 
activation of the WNT/β-catenin signaling pathway rather seems to inhibit the proliferation 
of B cells (see Figure 22 & Figure 25). This theory is also supported by the fact, that 
nuclear β-catenin is only detectable in few CLL cases (Tandon et al., 2011). Also in line 
with these results are stimulation experiments with WNT3a and WNT5a on CLL cells 
performed by Francesca Tettamanzi (see Supp. Fig. 1 & Supp. Fig. 2). In both cases, one 
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aiming on WNT/β-catenin activation and one on activation non-canonical WNT signaling, 
no supportive effect on CLL cell survival was detectable. A similar observation was made 
with more than 25 different activators of the WNT signaling pathways. This included eight 
different GSK3 inhibitors, which potently induce WNT/β-catenin in different cell types, but 
failed to support the viability of primary CLL cells (see Figure 37). But these substances 
not only failed to support the viability but many of them even proved to decrease CLL cell 
viability. The only drug able to increase CLL cell viability was QS-11, a substance reported 
as WNT3a co-activator of the WNT signaling (Zhang et al., 2007). Interestingly QS-11 
seemed to support CLL cell viability in a WNT3a independent mechanism in CLL cells 
(Supp. Fig. 3). Taken together it appears more and more likely that the β-catenin 
independent activation of LEF1 and the other TCFs in CLL is more important than the 
transactivation by β-catenin itself. This raises the question which other factors play a 
significant role in this regard.  
 
β-catenin independent transactivation of LEF1  
In many cancers and leukemia stem cell signaling pathways are exceptionally active and 
support survival and proliferation of the malignant cell. This is also the case in CLL. Next 
to the WNT signaling pathway also TGF-β, hedgehog and the NOTCH signaling cascades 
are aberrantly regulated in primary CLL cells (Desch et al., 2010; Douglas et al., 1997; 
Rosati et al., 2009). Surprisingly CLL cells express and secrete the TGF-β, a ligand with 
apoptosis inducing properties in B cells. CLL cells are resistant to TGF-β induced 
apoptosis, as Douglas and colleagues showed in 1997 (Douglas et al., 1997). In regard 
to WNT signaling, TGF-β was shown to be able to transactivate LEF1 via SMADs (Labbé 
et al., 2000). This pathway crosstalk is quite common and known to take place for example 
in stem cells and osteoblast (Cai et al., 2013; Letamendia et al., 2001). This could be a 
potential source for LEF1 transactivation in primary CLL cells. Apart from TGF-β the 
hedgehog signaling pathway might play a role in apoptosis resistance of CLL cells. 
Especially the transcriptionfactor GLI appears to be important to mediate this effect 
(Desch et al., 2010; Hegde et al., 2008). The HH and the WNT signaling pathway often 
work in concert to regulate cell differentiation and proliferation for example in pluripotent 
stem cells (Cerdan and Bhatia, 2010). The pathway crosstalk between the HH and WNT 
signaling pathway appears not to be as direct as for the TGF-β signaling cascade, but it 
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is highly likely to play a role for CLL (Seke Etet et al., 2012). Out of the three above-
mentioned pathways, the NOTCH signaling pathway most likely plays an outstanding role 
in LEF1 transactivation in CLL. First evidence about active NOTCH signaling in CLL 
emerged in 2002 as Hubmann and colleagues showed the regulation of CD23 on primary 
CLL cells by NOTCH2 (Hubmann et al., 2002). Later studies revealed a constitutive 
activation of pathway in the majority of CLL cases, which apparently also mediates cell 
survival of the leukemic cells (Rosati et al., 2009). In a whole genome sequencing 
approach, NOTCH1 mutations belonged to the most frequent mutations in CLL (Puente 
et al., 2011). Most of these mutations occur in the PEST domain of the ICD (intracellular 
domain) of NOTCH1 and are associated with an unfavorable outcome (Willander et al., 
2013). Interestingly the ICD domain of NOTCH1, which is cleaved from the receptor upon 
ligand binding, is also able to physically interact with LEF1 and to induce LEF1 dependent 
transcription in a β-catenin independent manner (Ross and Kadesch, 2001). Ross and 
Kadesh also postulated that the transactivation of LEF1 by the NOTCH1 ICD also 
regulates different genes when compared to the transactivation by β-catenin. It is obvious 
that the LEF1/NOTCH interaction is independent from the β-catenin binding domain of 
LEF1, as the interaction site was mapped to the HMG domain (Ross and Kadesch, 2001). 
This additionally allows for transactivation of LEF1ΔN, which is also expressed in CLL, 
but is regarded as inhibitor of the WNT/β-catenin signaling (Wang et al., 2005). 
Unfortunately, the focus of the major publications about LEF1 expression in CLL is on the 
full length LEF1 isoforms and leaves out ΔN isoforms or do not distinguish between both, 
therefore little is known about their ratio (Erdfelder et al., 2010; Gutierrez et al., 2010b). 
The only work dealing with the expression of the other isoforms has a too limited sample 
number for significant results, but suggests that the ΔN isoform is rather highly expressed 
in CLL compared to the full length sequence (Wang et al., 2005). The activation by 
NOTCH1 therefore becomes even more interesting as it has the potential to make use of 
the complete LEF1 pool in CLL.  
Taken together, it is obvious that LEF1 expression and NOTCH1 activation appear jointly 
in many CLL cases. A high LEF1 expression and NOTCH1 ICD mutations are associated 
with worse prognosis and the NOTCH1 ICD can transactivate LEF1 independent of its β-
catenin binding domain. All this evidence rather highlights the importance of 
LEF1/NOTCH interaction in CLL, which should be addressed in future in vivo experiments. 
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6.6 Targeting the WNT signaling pathway in CLL 
Since the first publication in 2004 about the activity of the WNT signaling pathway in CLL, 
several approaches have been used to inhibit WNT/β-catenin signaling in order to induce 
apoptosis in CLL cells. In the term of these experiments the WNT signaling pathway was 
proven to be a quite selective target, since most mature cells do not express it 
(Gandhirajan et al., 2010; Razavi et al., 2011). This effect can also be observed in Figure 
38, in which the influence of 50 different WNT inhibitors on the viability of CLL cells as 
well as on PBMCs and B cells from healthy patients was tested. Most inhibitors, if not 
generally toxic like pyrvinium pamoate or completely ineffective, proved to be more or less 
selective on CLL cells (see Figure 38). Interestingly, the majority of WNT inhibitors, with 
few exceptions like JS-K and NO-ASA, which target either β-catenin or the β-catenin/TCF 
complex directly, had little impact on CLL viability. These results suggest that β-catenin 
dependent signaling plays only a minor role in in vitro CLL cell survival, but there is also 
evidence for the opposite. Gandhiranjan and co-workers used two small molecules which 
inhibit complexation of β-catenin with TCF/LEF1 transcriptionfactors. They were able to 
show that this substances can selectively drive CLL cells into apoptosis (Gandhirajan et 
al., 2010). However, it is unclear if both small molecules are truly specific to the inhibition 
of the transcription complex. The situation for JS-K, one of the effective substances of the 
inhibitor screen that targets β-catenin, is quite similar (see Figure 38). While originally 
reported to selectively inhibit the WNT/β-catenin pathway, later publications rather 
focused on its ability to inhibit androgen-receptor signaling (Laschak et al., 2012; Nath et 
al., 2010). These two processes are clearly not independent but it cannot be excluded that 
the impact of JS-K on CLL cells is rather due to the inhibition of androgen receptor 
signaling (see Figure 38). Also the second example of a substance, the NO-ASA, which 
targets β-catenin and effectively and selectively drives CLL cells into apoptosis, offers 
some doubts about its role as a selective WNT inhibitor. NO-ASAs, especially the potent 
para-isomer, were regarded as effective WNT inhibiting drugs for experimental treatment 
of CLL (Kashfi and Rigas, 2005; Razavi et al., 2011). However, also other pathways seem 
to be affected by this group of compounds. Para and meta-NO-ASA are reported to affect 
especially the NF-κB, the Jun and Akt signaling pathways (Chattopadhyay et al., 2010; 
Rigas, 2009). The changes in the mRNA expression pattern induced by pNO-ASA and 
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mNO-ASA also showed no change of WNT related genes (see Figure 39). Significant 
changes in mRNA expression were only observed for pNO-ASA treatment, which 
especially induced the expression HSPs and other associated genes. This rather hints for 
a regulation of the NFκB signaling pathway. The gene expression arrays also show an 
increase of DNA-damage response genes like GADD45 (see Figure 39). This suggests 
that at least pNO-ASA might have some DNA damaging properties, but this effect could 
also be caused by other influences like apoptosis. Nevertheless, the promising results 
published by Razavi and co-workers justified a continuation of the scientific work 
regarding NO-ASA as experimental drug for CLL treatment (Razavi et al., 2011).  
 
6.6.1 NO-ASAs 
The NO-ASAs are a special group of experimental compounds, which combine a 
traditional acetylsalicylic acid with a nitric oxide donating moiety. They are under 
investigation due to their antineoplastic properties, which exceed the efficacy of aspirin by 
more than 1000 times in vitro (Kashfi et al., 2002). Originally the main focus of research 
was on mNO-ASA, which was put forward for preventive treatment of gastrointestinal 
cancer (Williams et al., 2004). The substance was tested in clinical trials, which were 
stopped due to concerns about genotoxicity (NicOx, 2007). Now the focus has mainly 
shifted to type 2 diabetes (Gresele et al., 2010). Unfortunately, the promising 
antineoplastic properties are no longer in the focus of the developing company, but some 
enhancements, especially to the more potent pNO-ASA are necessary for its future use. 
Therefore a substance library was generated in a cooperation of the organic chemistry 
and the Clinic I for Internal medicine of the University of Cologne (see Supp. Fig. 4). This 
library was tested for its potential to induce apoptosis in primary CLL cells (see  
Supp. Table 1). Especially interesting was that most child compounds with changes in 
acetylsalicylic acid group, like B2, B3 or B6 showed a similar efficiency compared to the 
parent compound NO-ASA (see  
Supp. Table 1). This shows that acetylsalicylic group seems to be dispensable for the 
antineoplastic effect of the drug. The notion is supported by Dunlap and colleagues who 
postulated that a chinone methide, a metabolite of NO-ASA that is formed from the benzyl 
linker, is responsible for driving cancer cells into apoptosis (Dunlap et al., 2008). This is 
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further supported by the fact that some pNO-ASA derivatives, especially those with an 
OTBS group instead of an NO moiety, like B4 and B7, fail to effectively induce apoptosis 
in primary CLL cells (see  
Supp. Table 1). This is probably reflects the fact that the OTBS link is very stable and 
therefore prevents the formation of the chinone methide. The antineoplastic effect seems 
to depend on the linker. This can also the third part of the NO-ASA molecule, the NO 
moiety too, can be replaced, for example by Cl (see Supp. Fig. 4; B12), without inhibiting 
its ability to induce apoptosis in primary CLL cells (see  
Supp. Table 1). From the in vitro experiments it became clear that the pNO-ASA child 
compounds B9, B12 and B13 were either equally effective and selective or superior when 
compared to their parent compound. This group of drugs shares the ability to inhibit the 
NFκB signaling pathway in primary CLL cells (Supp. Fig. 5 & Supp. Fig. 6). It appears that 
especially the inhibition of this pathway is a common feature among NO-ASAs with the 
ability to effectively drive CLL cells into apoptosis. This notion is also supported by strong 
regulation of HSPs in the mRNA expression array, which also suggests an involvement 
of the NFκB pathway in reaction to the treatment with the parent compound (Figure 39). 
In 2010 it was shown that NO-ASA can induce S-nitrosylation of p65, a central messenger 
protein of the NFκB signaling pathway (Chattopadhyay et al., 2010). In opposition to this 
findings is the fact that B12, which does not carry NO necessary for nitrosylation, can 
inhibit the NFκB activity, too (see Supp. Fig. 4 & Supp. Fig. 6). Therefore it is unlikely that 
the inhibition of the NFκB pathway is solely due to p65 nitrosylation. Other pathways like 
the AKT and the BTK showed no obvious regulation by the four effective NO-ASAs 
derivatives (personal communication with Sylvia Krallmann). A contribution to a inhibition 
of the WNT signaling pathway, like shown by Razavi end co-workers, can by no means 
be excluded at the moment, but it might not be of the highest relevance (Razavi et al., 
2011). One of the possible links between NO-ASA’s anti-neoplastic and the WNT 
signaling effect is ATF2. ATF2, which can transactivate LEF1 and therefore induce WNT 
dependent gene expression, and it was shown to be phosphorylated upon pNO-ASA 
treatment (Grumolato et al., 2013; Hua et al., 2009). If such a link exists and is of any 
relevance in CLL, will have to be clarified by future studies. 
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NO-ASA treatment in vivo 
To estimate the potential of a compound as a drug for CLL treatment it is necessary to 
test its efficiency and selectivity as well as to determine its bioavailability and agreeability. 
The last two aspects can only be tested in whole organisms. Unfortunately there are few 
practicable mouse models for the chronic lymphocytic leukemia available. Models like the 
Eμ-TCL1 strain develop a CLL like disease, but with a late onset which usually is after 
three to six month and is not predictable (Bichi et al., 2002). A transplantation of the 
leukemic B cells from this strain to wild type mice is possible, yet still this model faces 
problems with host-vs-graft effects (Hofbauer et al., 2011). It is also possible to transplant 
human CLL cells, which can engraft and induce leukemia in mice (Dürig et al., 2007). This 
model however suffers from the great versatility of human CLL cells, which can act quite 
differently towards treatment dependent on the donor (Dürig et al., 2007). Therefore a 
simpler model was chosen to test the agreeability and the bioavailability of the pNO-ASA 
derivatives in vivo. In this model JVM3 cells are injected subcutaneous into 
immunoincompetent mice. The cell line was isolated from a pro-lymphocytic chronic B cell 
leukemia patient and forms a solid tumor when injected subcutaneously. The cell line is 
susceptible to NO-ASA treatment, which is important to show if a drug is bioavailable 
(Razavi et al., 2011). In the in vitro experiments especially B9, B12 and B13 proved to 
effectively and selectively induce apoptosis in primary CLL cells (see  
Supp. Table 1). Of the three candidates B9 and B13 were chosen to be tested in vivo due 
to their superior selectivity and efficacy. Both substances are highly hydrophobic and 
cannot be dissolved in watery solutions, like pNO-ASA. Therefore the administration route 
and the vehicle were adapted when compared to the experiments performed by Razavi 
and co-workers (Razavi et al., 2011). Both substances are easily solvable in sesame oil 
at adequate concentrations and the oil alone, injected intraperitonealy, was well tolerated 
by the control group. The injection of B9 and B13 affected the tested mice for about 30 
min. The mice especially showed decreased locomotion. Usually after 15 min, the mice 
started to recover and resumed feeding, drinking and self-grooming. It has to be noted 
that the vehicle control group showed similar signs of distress, but recovered faster. Over 
the term of the experiment the bodyweight was used as one indicator for health status. 
Neither treatment resulted in an overall loss of bodyweight (data not shown). Mice 
examined after the conclusion of the experiment, also showed no differences of the 
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internal organs. The treatments neither resulted in lesions at the gastrointestinal tract, the 
kidney or the liver. The liver was not abnormally enlarged in mice of the treatment groups 
(data not shown). Therefore the drugs seemed overall quite agreeable, even if the 
administration and the used vehicle definitively have great potential for improvement.  
Of the two tested substances only B9 had a significant effect on the tumor growth (see 
Figure 41). A significant difference between the B9 treated and control mice is obvious 
after day 9. From day 9 to the end of the experiment the effect of B9 becomes highly 
significant and reaches the maximum inhibition ratio of 65% on day 17. This is lower when 
compared to the results which were achieved by Regina Razavi and colleagues for the 
parent compound (Razavi et al., 2011). Their experiments showed a maximum inhibition 
of the tumor growth of 83.4%, but it has to be noted that they used a far higher dosage 
and administered their drug orally (Razavi: 100 mg/kg per day vs. B9: 8 mg/kg every 2nd 
day). In consideration of the different molar mass of pNO-ASA and B9, only 1/20 of the 
dosage was used in the current study (compare Razavi et al., 2011). Therefore, it cannot 
be deduced that B9 is less effective, when compared to pNO-ASA. The experiment also 
showed that B13 was not effective in the used concentration or not bioavailable (see 
Figure 41). It is obvious that tumors of the B13 treated mice grow as fast as tumors of the 
control group. It is unlikely that this effect is due to dosage issues, as B13 was comparable 
effective in driving primary CLL cells into apoptosis (see  
Supp. Table 1). Therefore the drug was either not bioavailable, detoxified or instable. 
Since sections of treated mice revealed not enlargement of the liver, it is reasonable to 
assume that the failure of the drug is most likely due to availability or stability issues.  
 
Benefits and drawbacks 
From the beginning of the development of NO-ASA, especially mNO-ASA as a more 
tolerable form of aspirin, the scientific focus has changed dramatically. Starting with their 
potential as painkillers, they have been under investigation for their anti-neoplastic 
properties and are now in clinical trials for type 2 diabetes mellitus treatment (NicOx, 
2011). It appears that their promising features as anti-cancers drug have been somewhat 
neglected in the recent years. One symptom of this trend is that only mNO-ASA has 
entered clinical trials until now, whereas pNO-ASA which appears to be more potent in 
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cancer cell killing was never put forward. This might be due to the rather unspecific 
process, which most likely is responsible for the cytotoxic effect of the drug. The 
postulated generation of quinone methide and subsequent depletion of GSH will take 
place in healthy cells as well as in cancer cells (Dunlap et al., 2008). The same is true for 
the S-nitrosylation of p53, p65 and β-catenin (Williams et al., 2011). This raises the 
question why some of the NO-ASAs have such a high selectivity towards their target cells 
and are quite agreeable in vivo (see  
Supp. Table 1 & Figure 41). For this effect several explanations are possible. First, the 
substances preferentially enter the target cells, which could be triggered by their chemical 
characteristics like size or hydrophobicity. A second explanation is the presence or 
amount of special enzymes, which are needed to metabolize the compound and release 
the cytotoxic moieties in the target cells. The last and probably most likely explanation is 
based on the possible target structures involved. For example CLL cells rely for survival 
on tonic signaling of several pathways like the NFκB signaling pathway, sensitive towards 
oxidative stress (Cuní et al., 2004; Shanafelt et al., 2005). Since NO-ASA probably affects 
both this aspects, the CLL cells are hit at two sensitive points, whereas B cells from 
healthy patients are not as sensitive to oxidative stress and do not depend on tonic NFκB 
signaling in order to survive. This might also include several other pathways, like for 
example the WNT signaling cascade. This can lead to a higher susceptibility of CLL cells 
towards the drug. Overall the mechanism behind the antineoplastic effect of NO-ASAs 
remains unclear.  
Nevertheless, pNO-ASA and B9 have proven to be efficient in vitro and in vivo. The EC50 
of pNO-ASA (5.8 µM) and B9 (1.8 µM) on primary CLL cells is acceptable, as well are the 
therapeutic windows in the in vitro assays (see  
Supp. Table 1). Especially B9 appears to be superior in this aspect. The cytotoxic effect 
on CLL is in both cases due to apoptosis induction, which was demonstrated by caspase 
3/7 activity assays (Personal communication Sylvia Krallmann). Also both substances 
reduce NFκB activity, which likely contributes to the cytotoxic effect (Supp. Fig. 5 & Supp. 
Fig. 6). If the WNT signaling or the redox status is affected in the CLL cells remains 
unclear. Interestingly, especially B9 was shown by Sylvia Krallmann, to exhibit its cytotoxic 
effect independently p53 and is still efficient in heavily pretreated patients (personal 
communications). Future scientist will have to weigh the apparently unspecific mode of 
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action and broad spectrum of target structures against the antineoplastic effect. However, 
it seems likely that, apart from CLL, also other cancers and leukemia might be susceptible 
to this kind of drug. It might prove to be a good alternative to alkylating agents, which still 
are the backbone of many therapeutic regimens. Until then, the administration of the 
drugs, especially B9, will need improvement before it can be used efficiently.       
    
6.7 Outlook 
R26lef1 mouse model 
The R26lef1 has great potential for future studies of the WNT signaling in vivo, but first the 
final proof of the LEF1 functionality should be acquired. For this a rescue experiment 
should be conducted, where the LEF1 KO model is combined with R26lef1 CMV-cre model. 
Apart from this prove of principle it would be helpful to cross the R26lef1 CD19wt/cre model 
with a WNT reporter strain like the Tg(Fos-lacZ)34Efu, which expresses the β-galactosidase 
when the WNT signaling pathway is active. With this crossbreeding it would be possible 
to determine if the WNT signaling pathway is more active in B cells with transgenic LEF1 
expression compared to control cells and at which stages of their development the effect 
occurs. This is especially interesting since the present and work from others suggest, that 
LEF1 is only active in the bone marrow residing B cells and their progenitors. Another 
part, which was largely neglected so far, is to what extent, if at all, the LEF1 expression 
also influences B cell maturation and response to pathogens. An additional fact about the 
R26lef1 mouse model is the lack of leukemic events, which was shown for the LEF1 HSC 
model (Petropoulos et al., 2008). This might be due to the WNT signaling activity, which 
might be below a certain threshold in this model. To further unbalance the WNT signaling, 
with special regard to B cell leukemia, a combination with KO models of WNT inhibitors 
or transgenic expression of β-catenin are feasible strategies. Most promising would be 
crossbreeding with Axin2 null mice or with Gt(ROSA)26Sortm1(Ctnnb1)Kem, a strain which 
expresses full length β-catenin in presence of the Cre recombinase. Both strategies, 
would lead to a tremendous increase of the activity of the WNT signaling pathway in the 
target cells. If surplus activation of the WNT signaling pathway will have any additional 
impact on the B cell development is unclear, but it would increases the possibility of a 
leukemogenic event considerably.  
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Apart from these more basic studies several other questions might be answered with the 
R26lef1 model. Especially with regard to the question of the leukemic potential of the WNT 
signaling pathways several options arise with the R26lef1 model. If the hyperactivation of 
the WNT signaling pathway, like described before, is not able to induce leukemic events 
combinations with known leukemia mouse models are thinkable. 
This allows to analyze if the LEF1 is supporting factor for leukemia like CLL in vivo. This 
question can easily be answered by combination of existing leukemia models like the Eµ-
TCL1 strain, which develops a CLL like disease, with the R26lef1 CD19wt/lef1 strain. This 
combination should shift the disease onset significantly. If the transgenic LEF1 expression 
supports the diseases, Eµ-TCL1 R26lef1 CD19wt/cre mice will develop the diseases earlier, 
most likely with a more aggressive course. This model is not restricted to Eµ-TCL1 mouse, 
but can be combined with other leukemia developing strains as well.  
However, more interesting remains the question what other, by themselves not 
leukemogenic factors, are necessary to induce leukemia in combination with the R26 lef1 
model. Most likely candidate is a combination with the NOTCH pathway. There are already 
adequate commercially available strains, like the Gt(ROSA)26Sortm1(Notch1)Dam/J strain. This 
strain does not produce B cell leukemia, even when the transgene expression is activated 
in lymphocytes. However a CD19wt/cre restricted expression of LEF1 and the NOTCH1 ICD 
will most likely activate LEF1/NOTCH1 dependent gene expression, which probably has 
a leukemogenic potential. A small drawback would be the complicated mating schemes 
since the NOTCH1 fragment and the LEF1 are both inserted in the Rosa26 locus. The 
R26NOTCH1/lef1 CD19-Cre model would closely simulate the conditions known from chronic 
lymphocytic leukemia and might result in an interesting disease model. It would also be 
possible to show LEF1 dependent transactivation by the NOTCH1 ICD in vivo, by 
crossbreeding with NOTCH and WNT reporter strains. For the WNT signaling pathway 
the Tg(Fos-lacZ)34Efu developed by Elaine Fuchs or the Axin2 promoter driven Axin2tm1Wbm 
model are options. For NOTCH pathway signaling the Tg(Cp-HIST1H2BB/Venus)47Hadj  is a 
possible reporter strain. It has to be noted that the latter reporter strain is based on Venus 
expression, a fluorescent protein, which cannot be easily distinguished from the GFP 
expression produced by the NOTCH1 and the LEF1 strain for expression control. It is still 
possible that no leukemia will be induced in R26NOTCH1/lef1 CD19wt/cre mice, but at least a 
significant impact on B cell development is to be expected. Corresponding to the 
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R26NOTCH1/lef1 model, the R26lef1 strain enables future scientists to test crosstalk with many 
other signaling pathways in distinct tissues, which sets the model apart from all other LEF1 
dependent mouse models.  
 
NO-ASA 
The NO-ASA derivatives, especially B9 have shown to be promising compounds for the 
treatment of chronic lymphocytic leukemia, but there are still several questions to be 
addressed. The first remains the original target affected by B9, since it is unlikely that, for 
example protein nitrosylation, is responsible for all the signaling pathway modulation 
observed in primary CLL cells. Therefore precipitation experiments, for example using the 
click chemistry, with subsequent analysis by mass spectrometry should be conducted. 
Also comparative analysis between the different NO-ASA derivatives should be 
performed, in order to describe family specific modulations. This will help to assess their 
potential as anti-cancer drugs. Additionally, the pharmacokinetics are more or less 
unknown and need to be analyzed. Experiments with labeled B9 should be conducted in 
vitro and in vivo. For the latter in vivo imaging, possibly in combination with a xenograft 
tumor model, would be advisable as strategy. Also more basic questions should be 
addressed in future experiments. So far B9 was solved in sesame oil for in vivo 
experiments and injected intraperitoneal. Neither the used vehicle nor the application 
procedure is suited for leukemia patients. Most convenient would be an oral administration 
or an intravenous injection. These routes would largely depend on the used vehicle. One 
option would be packaging of the drug, for example into liposomes. Another possibility are 
further structural changes of B9, for example at the benzoate group, which appears to be 
dispensable for the anti-neoplastic effect, to decrease the lipophilic character. But these 
changes always bear the risk to reduce the overall performance of the drug. So far the 
spectrum of tested neoplasia is still very restricted. Future experiments should also 
include other cancers, since it is to be expected that they will prove sensitive towards the 
compound, too. It would also be advisable to check other properties of the new derivatives, 
apart from cancer treatment. Since mNO-ASA is under investigation for its ability to 
improve the insulin sensitivity of diabetes type 2 patients, similar properties are also 
thinkable for other NO-ASAs. Overall future experiments are needed to address the 
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administration, pharmacokinetics, molecular target structures and possible side effects. 
Additionally an extension of experiments to other cancers and diseases is desirable. 
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8 Additional Information 
8.1 Supplemental data 
 
Supp. Fig. 1 WNT3a CLL cell survival upon stimulation with increasing concentrations of Wnt3a after 48 h. CLL 
cells were treated with rhWnt5a or BSA (1 ng/mL, 10 ng/mL, 100 ng/mL, 200 ng/mL and 500 ng/mL). After 48 h 
cells were collected, stained with Annexin V/7AAD and tested for survival through FACS. Values were 
normalized to UTR control. Number of experiments n=3. [Performed by Francesca Tettamanzi] 
 
 
Supp. Fig. 2 WNT5a CLL cell survival upon stimulation with increasing concentrations of Wnt3a after 48 h. CLL 
cells were treated with rhWnt5a or BSA (1 ng/mL, 10 ng/mL, 100 ng/mL, 200 ng/mL and 500 ng/mL). After 48 h 
cells were collected, stained with Annexin V/7AAD and tested for survival through FACS. Values were 
normalized to UTR control. Number of experiments n=3. [Performed by Francesca Tettamanzi] 
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Supp. Fig. 3 Influence of the proposed synergistic action of QS-11 and rhWnt3a on CLL cell survival under 
normal (A) or serum starved conditions (B). CLL cells were incubated with QS-11 (10 μM), rhWnt3a (100 ng/mL) 
or a combination of the two molecules under normal or serum starved conditions. DMSO control was also 
included. After 24h CLL cells were collected, subjected to Annexin V/7AAD staining and tested for viability 
through FACS. Number of experiments n=6. [Performed by Francesca Tettamanzi] 
 
 
Supp. Fig. 4 Chemical structure of newly developed NO-ASA derivatives [Sylvia Krallmann] 
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No. CLL cells  
EC50 [µM] 
healthy PBMCs  
EC50 [µM] 
pNO-ASA 5.582 53.89 
B2 4.745 48.50 
B3 3.945 > 150 
B4 > 150 > 150 
B5 37.20 96.57 
B6 4.419 183.6 
B7 52.78 > 150 
B8 57.31 > 150 
B9 1.835 79.54 
B10 79.42 > 150 
B11 14.65 20.08 
B12 1.332 141.7 
B13 1.043 121.1 
 
Supp. Table 1 EC50 of NO-ASA Derivates on primary CLL and PBMCs from healthy patients. Primary CLL cells 
and PBMCs (1*107 cells/ml) were cultivated in Medium A for 24h treated with a compound (range 1-100 µM) or 
with vehicle control. Survival was analzed via Annexin V/ Propidium iodide assay with FACS. Experiments and 
analysis performed by Alexandros Liakos. 
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Supp. Fig. 5 NFκB Phosphorylation status. CLL cells were treated for three hours in with the substance 
indicated or DMSO as vehicle control. Cells were harvested lysed and probed for p- NFκB and total NFκB. 
GAPDH serves as loading control. Experiment was performed at least three times by Sylvia Krallmann 
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Supp. Fig. 6 NFκB Phosphorylation status. CLL cells were treated for three hours in with the substance 
indicated or DMSO as vehicle control. Cells were harvested lysed and probed for p- NFκB and total NFκB. 
GAPDH serves as loading control. Experiment was performed at least three times by Sylvia Krallmann 
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Supp. Fig. 7 Health status of the animal facility July 2011-June 2013. Health monitoring was performed 
according to the recommendation by the FELASA for standard pathogen free facilities. The list shows number 
of tested animals vs. number of positively tested cases. Red indicates positive results.  
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